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ABSTRACT 
Extracellular matrix (hMatrix) derived from osteogenically enhanced mesenchymal stem 
cells (OEhMSCs) can be deposited onto scaffolds in a process referred to as “bioconditioning”. 
While bioconditioned gelatin scaffolds have been shown to enhance stem cell retention and 
significantly accelerate repair of critical-sized bone defects, there is a need for alternative 
biofabrication methods that have greater clinical potential in bone regenerative therapies. 
Injectable delivery vehicles are desirable because of their ability to space-fill defects and form a 
continuous interface with existing bone. Herein, we report gelatin methacrylate (GelMA) 
microspheres fabricated using a custom 3D-printed coaxial flow focusing device. We demonstrate 
that OEhMSC attachment to the hMatrix coating stimulates the secretion of osteogenic and 
angiogenic factors and upregulates BMP-2 gene expression. OEhMSCs delivered with 
microspheres coated with hMatrix enhanced bone regeneration in a murine femoral defect model 
compared to bare microspheres. OEhMSCs administered with microspheres coated with hMatrix 
also supported bone regeneration comparable to that induced by the current gold standard of BMP2 
delivered from a collagen sponge in a murine calvarial defect model. These results indicate the 
hMatrix/OEhMSC composite microspheres are effective vectors for delivery of stem cells for bone 
regeneration.  
While a versatile space-filling delivery method has many benefits, customized, patient-
specific 3-D grafts can also allow for good tissue integration with an increased level of 
sophistication from control over the hierarchical structure. Additive manufacturing is a promising 
method for producing these customized three-dimensional bioactive constructs for regenerative 
medicine. While thermoplastics and metal implants have been successfully used for permanent, 
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non-degradable craniomaxillofacial implants in adults, these materials lack bioactive 
characteristics to degrade and allow for neotissue formation that can grow with young patients. 
Therefore, we also demonstrate a workflow for a 3D bioprinted osteoinductive bone graft using an 
innovative hydrogel ink conjuncted with the bioconditioning process to direct osteogenic 
differentiation of human mesenchymal stem cells (hMSCs). Specifically, we printed freestanding 
bone graft geometries using a Nanoengineered Ionic-Covalent Entanglement (NICE) bioink. 
Bioconditioning NICE with a matrix deposited by osteo-enhanced hMSCs (iP-hMatrix) derived 
from human induced pluripotent cells resulted in a significant increase in mineralization and 
deposition of collagens VI and XII that contribute to the osteogenic activity of iP-hMatrix. 
Bioconditioned NICE increased the expression of osteogenic marker genes, including bone 
morphogenic protein-2, osteocalcin and osteopontin. These results suggest that bioconditioning 
NICE scaffolds using iP-hMatrix enhances osteogenic potential of the scaffold and can be used for 
craniomaxillofacial bone grafts with precise geometries. 
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1. INTRODUCTION AND LITERATURE REVIEW
1.1 Clinical Need-Critical Size Bone Defects 
Of the 5.6 million bone fractures that occur annually in the United States, about 10% fail 
to repair [1]. Additionally, bone defects due to severe trauma, tumor resection, congenital defects, 
disease, and non-union fractures may not heal adequately. Fractures and minor bone defects 
naturally undergo regenerative healing with proper fixation. However, critical sized bone defects 
result in incomplete healing and need surgery to repair the bone defect. Key’s hypothesis states 
that a segmental long bone defect 1.5 times the diaphyseal diameter exceeds the regenerative 
capacity of bone in skeletally mature dogs and results in a critical size bone defect [2]. Therefore, 
researchers have utilized critical size bone defects as an experimental model to examine the 
effectiveness of their bone graft materials. 
1.1.1 Bone Biology 
Bone is a natural composite of organic collagen fibrils and inorganic mineral 
hydroxyapatite. Hydroxyapatite provides bone with mechanical rigidity and load-bearing strength 
while collagen fibrils provide elasticity and flexibility [3]. Calcified bone is comprised 
approximately of 25% organic matrix, 5% water, and 70% inorganic mineral hydroxyapatite [4]. 
Osteoid, newly secreted matrix before mineralization, contains about 94% of collagen and proteins 
are stored in the matrix that are important for cell signaling and the mineralization process [4]. 
Bone is further classified into two types: cortical and cancellous. Cortical bone, the outer layer of 
bone, is dense with a low porosity (~5-30%) which results in the high compressive strength (~170 
MPa) [5]. Cortical bone also makes up 80% of the skeletal mass [3] and is found in the diaphysis 
of long bones. A detailed diagram of the anatomical features of bone is shown in (Fig. 1.1) [6]. 
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Cancellous bone, also called spongy bone, has a honeycomb like structure with a high porosity 
(~30-90%) which results in a lower compressive strength (~7.5 MPa) [5]. Cancellous bone makes 
approximately 20% of the skeleton [3] and makes up the metaphysis of long bones. The periosteum 
is a thin membrane that surrounds the outer cortical surface of bone and contains blood vessels, 
nerve fibers, and progenitor cells [3]. Bone involves a dynamic relationship between osteoclasts, 
which resorb bone, and osteoblasts, which secrete a supportive extracellular matrix and regulate 
its mineralization. Osteocytes are mature osteoblasts that have become embedded in extracellular 
matrix they secrete and are the most abundant cells in bone. 
Figure 1.1. Bone physiology. Reprinted from [6]. 
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1.1.2 The Bone Healing Process 
Bone is a unique tissue in that it does not heal with a fibrous scar as do nearly all other 
tissues [7]. The three stages of bone healing are inflammation, regeneration, and remodeling. 
Immediately after an injury, an inflammatory phase is initiated, which peaks at 24-48 hours and 
disappears 1 week after the bone fracture. During the inflammatory phase of healing, a hematoma 
develops at the bone fracture site and inflammatory cells and fibroblasts are recruited [8]. This 
results in the formation of granulation tissue, vascular ingrowth, and mesenchymal stem cell 
migration to fracture site [8].  
 The regeneration phase starts within the first few days of the injury and lasts for several 
weeks. The regenerative phase results in a soft callus which helps enhance mechanical stability of 
the bone fracture which is slowly resorbed as new bone is deposited. The regeneration phase starts 
with fibroblasts depositing a stroma that stimulates vascular ingrowth. The vascularization process 
is mainly regulated by vascular endothelial growth factor (VEGF) and angiopoietin [9]. As 
vascular ingrowth advances osteoblasts secrete an osteoid, unmineralized matrix composed of 
collagen type I and glycosaminoglycans, which is over time mineralized and forms a bony callus. 
During the first 4 to 6 weeks, the callus is very weak and requires immobilization. In time the 
callus ossifies to bridge woven bone between the bone fractures. However if the bone fracture is 
not immobilized correctly, the callus may not ossify and instead forms a cartilaginous callus which 
results in a hypertrophic non-union [10]. Simultaneously, intramembranous ossification occurs 
subperiostally adjacent to the proximal and distal ends of the bone fracture producing a hard callus 
[10]. 
The final stage of bone healing is the remodeling phase and may occur at the fracture site 
for up to a few years [8]. The remodeling phase is stimulated by mechanical loading as stated in 
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Wolff’s law [11]. Sufficient strength is usually attained in 3 to 6 months [8]. The remodeling phase 
starts with the replacement of woven bone by mature lamellar bone and resorption of the callus 
[12]. After all woven bone is replaced, poorly located trabeculae are resorbed by osteoclasts and 
new bone regenerates along lines of stress. During the remodeling phase, the bone fracture healing 
is completed when the bone is repaired to the original shape, structure, and mechanical strength 
[8].  
Regenerating bone contains high amounts of collagens VI and XII. Collagen type VI 
expression is high throughout the fracture healing process and low in unfractured bone [13]. Also 
collagen type VI has shown to be highly expressed by mesenchymal stem cells during embryonic 
development and at birth and expression decreases to low levels in adults animals [14]. Collagen 
type XII has been detected in developing vertebrae and long bones [15]. In Chapters 2 and 4 
collagens VI and XII will be incorporated into injectable microspheres and 3D printed scaffolds 
to fabricate bone tissue engineering scaffolds that mimic regenerating bone.  
1.1.3 Bone Healing In Critical Size Defects 
The bone healing in critical and non-critical size bone defects are similar in principle in 
that they include the formation of a callus that proceeds towards bridging of the bone fracture. 
However in a critical size bone defect, the callus of opposing osteotomy ends was not in contact 
and therefore full bridging did not occur [16]. Therefore since bridging does not occur, this results 
in a decreased transmission of load which is needed for bone restructuring and reorientation [16]. 
Instead, the marrow cavity closes and rounded cortices are formed [16]. 
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1.1.4 Endochondral and intramembranous ossification 
New bone formation occurs via endochondral or intramembranous ossification. Examples 
of bones formed by intramembranous ossification include: the flat bones of the skull, mandible, 
and collarbones. Intramembranous bone formation is achieved by direct mesenchymal stem cell 
differentiation into osteoblasts which secrete an osteoid matrix, as shown in (Fig. 1.2A). Long 
bones form via endochondral ossification. In endochondral ossification, mesenchymal stem cells 
undergo chondrogenesis and form a cartilaginous callus that is then calcified into bone (Fig. 1.2B). 
In the first step, capillaries grow around the cartilage anlage. In the second step, chondrocytes 
hypertrophy in the center of cartilage and express vascular endothelial growth factor (VEGF) 
which allow for capillaries to enter. In the third step, the hypertrophic cartilage is replaced with 
bone and marrow and growth plates are formed. In Chapter 3, both calvarial and femoral defect 
models are used to evaluate healing and ensure that the bone graft works in bones formed by both 
intramembranous and endochondral ossification.  
6 
Figure 1.2. (A) In intramembranous ossification, mesenchymal stem cells condense at sites of bone 
regeneration. The mesenchymal stem cells then differentiate to osteoblasts and directly secrete a bone matrix. (B) In 
endochondral ossification, mesenchymal stem cells first differentiate into chondrocytes and form cartilage which is 
then followed by replacement with bone. Reprinted from [17].  
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1.2 Current Treatment Options 
Current treatments for repairing bone defects have their advantages and disadvantages. 
These treatments can be organized into three categories: autografts, allografts, and synthetic 
materials. Tissue engineering combines stem cells, bioactive cues, and a biomaterial scaffold 
which can be implanted to restore function.  Depending on the source of these components, it 
combines aspects of these 3 types of grafts.  
1.2.1 Autografts 
Autologous bone grafts are the current gold standard used to heal critical sized bone defects 
due to their osteoconductive, osteoinductive, and osteogenic properties [18]. Bone is commonly 
harvested from the patient’s iliac crest and implanted into the bone defect. One of the most 
common uses for autografts are vertebral fusions, which generally have high success rates [19]. 
However, the available graft material is limited and there are complications from introducing a 
second surgical site which has been shown to cause chronic donor site pain and morbidity in many 
patients [19-21]. 
1.2.2 Allografts 
Allogeneic bone grafts, or allografts are harvested from the same species as the recipient 
and typically derived from cadavers from tissue banks [22]. Allografts are commonly used to 
augment graft volume for orthopedic procedures or to avoid the need for a secondary procedure to 
obtain autologous grafting material. [19]. However, allografts can have reduced healing potential 
and mechanical properties due to processing and decellularization as well as the risk of disease 
transmission and immune response.  
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1.2.3 Synthetic Materials 
A variety of synthetic materials have been used in bone tissue engineering which include 
stainless steel, titanium, methyl methacrylate resins, and hydroxyapatite ceramics. Synthetic 
materials are abundantly available and highly tunable, but fail to provide adequate endogenous 
factors that promote cell behavior such as cell adhesion, proliferation, and differentiation [23, 24]. 
Drawbacks inherent to the use of these synthetic materials include limited biodegradability, 
inadequate tissue integration, and bone resorption due to stress-shielding. While many great strides 
have been made to optimize synthetic grafts, a manufacturable graft with the healing potential of 
tissue-derived materials would enhance the standard of care for procedures involving bone grafts. 
1.3 Tissue Engineered Bone Grafts 
Tissue engineering aims to fabricate tissue grafts that combine the regenerative capacity of 
autologous tissue with the availability of synthetic scaffolds [25]. This is accomplished by 
combining cells to facilitate tissue formation, bioactive cues to direct the growth and 
differentiation of cells, and a biomaterial scaffold to provide a substrate for tissue regeneration 
[26]. Previous work has indicated that an optimal tissue engineered bone graft should be 
degradable to allow room for tissue growth [27, 28] and deliver human mesenchymal stem cells 
(hMSCs) in an appropriate carrier with the correct bioactive factors to direct stem cell fate to 
osteoblasts [29]. Injectable materials are considered ideal delivery systems because of their ability 
to space-fill the defect and form a good interface with existing bone to encourage bone remodeling 
and healing [22, 28]. 
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1.3.1 Hydrogels as Tissue Engineering Scaffolds 
Hydrogels are highly hydrated 3D networks that mimic the native soft tissue 
microenvironment. Hydrogels are an attractive material due to their high permeability for oxygen, 
nutrients, and soluble factors [30]. Furthermore, many hydrogels are fabricated under mild, 
cytocompatible conditions that facilitate cell encapsulation and are easily modified to possess 
integrin binding sites and enzymatically degradable segments [31]. Currently, the hydrogels used 
for tissue engineering range from natural to synthetic with each system having its own advantages 
and limitations (Table 1.1 and 1.2). 
Table 1.1. Advantages and disadvantages of natural hydrogels. 
Advantage Disadvantage 
Biocompatible Tuning material properties difficult 
Biodegradable Batch-to-batch variability 
Bioactive Poor mechanical properties 
No immune response Animal-based origin 
Table 1.2. Advantages and disadvantages of synthetic hydrogels. 
Advantage Disadvantage 
Highly reproducible 
Lack endogenous factors that promote cell 
behavior 
Tunable mechanical properties 
Non-degradable materials inhibit tissue 





Natural hydrogels are typically fabricated using collagen, gelatin, alginate, or Matrigel (a 
mixture of native ECM proteins). These natural materials are inherently biocompatible, bioactive, 
and have similar mechanical properties to native tissue [32]. They also contain endogenous signals 
that promote cell viability, proliferation, differentiation, and migration. However these natural 
materials are complex and it can be difficult to determine what signals are promoting cell functions 
[23]. Furthermore, tuning the material properties such as matrix stiffness and degradation rate can 
be difficult and there is batch-to-batch variability which confounds the effect of the scaffold. 
Hydrogels can also be formed of synthetic, covalently crosslinked molecules such as poly(ethylene 
glycol) diacrylate (PEGDA). When a PEGDA hydrogel is implanted into a bone defect, this results 
in fibrotic scar formation with little or no bone growth (Fig. 1.3). However, when a PEG hydrogel 
with MMP-degradable linkages is implanted, scaffold degradation allows for neotissue formation 
[33]. 
Figure 1.3. (A) Masson’s trichrome on non-degraded PEGDA scaffold implanted 9 weeks post-implantation in 
calvarial defect. Surrounding the PEGDA scaffold there is a fibrous capsule and limited bone regeneration. (B) 
Masson’s trichrome on PEG-MMP scaffold implanted 9 weeks post-implantation in calvarial defect. The scaffold is 
degraded and there is bone regeneration in area previously occupied by the scaffold. Reprinted from [33]. 
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Synthetic hydrogels are highly reproducible and have tunable mechanical properties. 
However, they lack the endogenous factors that promote cell behavior. There is a need for a 
hydrogel scaffold that combines the benefits of natural and synthetic hydrogels while also 
incorporating essential bioactive cues to help guide stem cell fate. 
1.3.2 Gelatin methacrylate (GelMA) hydrogels 
Gelatin is inexpensive, denatured collagen and can be functionalized with methacrylate 
groups to form gelatin methacrylate (GelMA) (Fig. 1.4A) [34]. GelMA can be UV crosslinked 
with the addition of a photoinitiator to fabricate a hydrogel (Fig. 1.4B). This characteristic gives 
GelMA hydrogels stability at physiological temperature and tunable mechanical properties. The 
resulting hydrogel is also transparent, facilitating microscopic imaging. Since gelatin is a 
hydrolysis product of collagen, it contains arginine-glycine-aspartic acid (RGD) sequences that 
promote cell attachment, as well as the target sequences for matrix metalloproteinase (MMP) 
mediated degradation. The GelMA hydrogel can therefore provide an environment that supports 
cell adhesion, proliferation, differentiation and ECM remodeling. Due to these attributes, GelMA 
is commonly used for cell culture models and tissue engineering applications [35]. 
The mechanical properties of GelMA can be tuned by varying the degree of methacrylate 
substitution, polymer and photoinitiator concentrations, and UV crosslinking time [36, 37]. 
Substrate stiffness is important for stem cell differentiation and can strongly influence stem cell 
behavior. Investigators have shown that substrate stiffness has a significant effect on MSC 
differentiation, with stiffer matrices (25-40 kPa) promoting osteogenic differentiation [38, 39] and 
softer matrices promoting neurogenic differentiation (0.1-1 kPa) [40]. It has also been shown that 
cells remain viable and elongated when adhered to or encapsulated in GelMA, indicating that the 
methacrylation does not disrupt these key properties (Fig. 1.4C) [34, 41]. Additionally, cells can 
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degrade the GelMA hydrogel, where the rate of degradation depends on the methacrylate 
substitution, cell type, and cell seeding density. 
Figure 1.4. Synthesis of gelatin methacrylate (GelMA) and cell adhesion on GelMA hydrogel. (A) Gelatin containing 
primary amine groups was reacted with methacrylic anhydride to add methacrylate pendant groups. (B) To fabricate 
a hydrogel network, methacrylated gelatin was UV crosslinked in the presence of the photoinitiator Irgacure 2959. 
(C) HUVEC cells adhered to GelMA on day 5 of culture. Reprinted from [34].
1.3.3 Mechanically Stiff Nanocomposite Hydrogels using Nanoparticles 
Collagen-based hydrogels have been extensively used because of their ability to 
encapsulate cells, non-immunogenic properties, and presence of cell binding motifs and Matrix 
Metalloproteinase (MMP)-sensitive degradation sites that permit matrix remodeling. Recently, 
studies have used carbon nanotubes [42, 43], silicate nanoparticles [44], and magnetic 
nanoparticles [45] to increase hydrogel mechanical stiffness. These nanoparticles electrostatically 
interact with the polymer chains resulting in an increase in the mechanical stiffness. Recently, 
Jaiswal et al. showed that magnetic nanoparticles at very low concentrations (less than 0.01% 
relative to polymer) resulted in a more than 10-fold increase in mechanical stiffness and 20-fold 
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increase in toughness [45]. Also, cells were able to be encapsulated within the nanocomposite 
hydrogel network, with the cells sensing and responding to the matrix stiffness. Overall, this 
demonstrates a new approach to increase the mechanical stiffness of collagen-based hydrogels 
using nanoparticles at a concentration 2-3 orders of magnitude lower than usual. 
1.3.4  BMP2 in Bone Tissue Engineering 
It is vital that bone tissue engineering scaffolds incorporate necessary bioactive cues for 
stem cells to differentiate into functional osteoblasts. A potent approach to improve the 
regenerative capacity of bone tissue engineered scaffolds and induce osteoblastogenesis is the 
incorporation of osteoinductive growth factors such as bone morphogenic protein-2 (BMP-2). 
BMP-2 has been commonly used in bone regeneration due to its importance during bone 
development and fracture healing. This has been translated to clinical use by Medtronic as the 
INFUSE bone graft. However, this graft has been scrutinized due to off-label use of BMP-2 which 
may result in unwanted outcomes such as ectopic bone growth, cancer, and inflammation [46-48] 
due to difficulty to control the correct release kinetics and concentration desired to stimulate the 
desired response. There is therefore a clear need for an implant that minimizes the use of growth 
factors that can achieve comparable bone regeneration to that caused by BMP-2. 
1.3.5 Cell-Derived Extracellular Matrices as Bone Tissue Engineering Scaffolds 
Decellularized cell-derived matrices (dECM) offer an attractive alternative to growth factors. 
dECM has been shown to contain tissue-specific bioactive cues that play a role in cell proliferation, 
differentiation, and maintenance of cell-specific phenotypes [49]. After decellularization, the 
remaining matrix-bound bioactive factors can interact with reseeded cells [49]. Xue et al. 
demonstrated that acellular cartilage sheets (ACSs) preserved the natural cartilage matrix including 
collagen type II and glycosaminoglycan content [49]. Also, ACSs possessed growth factors 
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including TGF-β1, IGF-1 and BMP-2 which induced bone marrow-derived mesenchymal stem 
cells to differentiate into chondrocytes [49]. Dr. Carl Gregory’s group has demonstrated that 
hMSCs treated with an peroxisome proliferator-activating receptor gamma (PPAR-γ) inhibitor, 
GW9662, reduces negative cross-talk on the cWnt pathway, resulting in an osteogenically 
enhanced hMSC (OEhMSC) phenotype [50]. OEhMSCs secrete an extracellular matrix (hMatrix), 
(Fig. 1.5A) that mimics the composition of anabolic bone tissue and strongly enhances hMSC 
retention and subsequent bone repair in vivo [50]. Zeitouni et al. repaired mice critical calvarial 
defects with OEhMSC-seeded hMatrix which resulted in 80-100% bone healing in 3 weeks (Fig. 
1.5B) [50]. Enhanced bone healing was attributed to increased cell retention at the defect due to 
presence cell binding sites on hMatrix. These studies establish the biological basis for the scaffolds 
that are developed in the following studies.  
Figure 1.5. hMatrix extraction and efficacy of GW-hMSC-hMatrix composites in healing calvarial defects in mice. 
(A) Decellularized hMatrix recovered from osteogenic monolayer cultures of hMSCs. (B) µCT of defects in explanted
calvaria (left) and axial reconstructions (right). Reprinted from [50]. 
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1.4 hMSCs in Tissue Regeneration 
hMSCs have the capacity to differentiate into different mesenchymal tissue lineages 
including bone, adipose, and cartilage. In certain conditions, hMSCs can also be induced to 
differentiate into other tissues such as myoblasts, cardiomyocytes, hepatocytes and neural cells in 
vitro. The remarkable plasticity of hMSCs in vitro and in animal models has been extensively 
reviewed in the literature [51-55]. An additional intrinsic property of hMSCs that helps aid in tissue 
regeneration is their ability to secrete a wide range of growth factors which has trophic effects on 
repairing tissues [56, 57]. hMSCs also have immunomodulatory properties and inhibit the 
proliferation of T-cells [58-60] and blunt the effects of antibody secreting B-cells [61, 62] due to 
their low expression of major histocompatibility complex (MHC) Class II and secretion of 
cytokines [63-65]. Due to all of these advantages, hMSCs have attracted much interest in their 
clinical potential for the treatment of numerous diseases such as osteogenesis imperfecta [66], 
coronary disease [67, 68] and regenerative therapy for a wide range of tissues including heart, 
spine, lung, bone, cartilage and tendon. However, there are several issues with translation of hMSC 
research, specifically the administration and retention of these cells, and the variability between 
patients that remain challenging. 
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Figure 1.6. Trends over time in 4749 stem cell clinical trials globally. Reprinted from [69]. 
1.4.1 Donor Variability 
hMSCs are the most commonly used cell source for tissue engineering applications and 
there has been an increase in MSC clinical trials globally since 2004 (Fig. 1.6). However, results 
from these clinical trials have not been as promising as in vitro and in vivo data. It has been 
proposed that donor variability in hMSC populations used in these clinical trials may be why they 
fall short of expectations. Several studies have shown donor variability in proliferation capacity 
[70-72], chondrogenic [70, 73, 74], osteogenic [70, 71, 75], adipogenic [70, 76], or endothelial 
[77] differentiation in hMSC culture. In one study, induction of osteogenesis with GW9662
resulted in significant increase in alkaline phosphatase (ALP) expression, an early osteogenic 
marker indicative of bone mineralization, but displayed marked variability between donors (Fig. 
1.7).  
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Figure 1.7. Human hMSCs from two donors were incubated in osteogenic media in the presence or absence of 10µM 
GW9662, and ALP activity was measured by colorimetric assay.  
The harvested cell population from each bone marrow tissue sample is heterogeneous and 
is comprised of different proportions of hMSCs at different stages of differentiation [71]. The 
heterogeneous cell population is evident by data showing varying levels of ALP enzyme activity 
between samples [71]. This shows that donor hMSC cultures are not a uniform population of 
osteogenic progenitors. Furthermore studies have shown that there is not only variability with 
donor age [75], but also in donors with similar age [70]. The tissue sampling method might also 
affect the heterogeneity of hMSC populations and may be responsible for donor variability since 
there are variations in hMSC properties between samples collected from the same donors at various 
times [71]. Alternatively, iPSCs can be used to produce iPSC-derived hMSCs (iP-hMSCs), which 
can theoretically be expanded indefinitely with reliable properties. These cells could then be 
utilized for the production of a scaffold or its components without needing to retain them in the 
final product. This would potentially eliminate the issue of variability and reduce immunological 
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complications. Chapter 4 will explore utilizing iP-hMSCs in 3D printed bone tissue engineering 
scaffolds.  
1.4.2 hMSC Retention 
Several animal studies have shown that even though stem cells are sparsely engrafted after 
administration, there is still a physiological improvement [78-89]. It is thought that this is the result 
of hMSCs providing support to adjacent tissues through the secretion of trophic factors that help 
limit tissue damage and enhance repair. Although the stem cells only transiently appear in the 
injured tissue, their effects on the adjacent tissues may be sustained long after the cells disappear 
[56]. However, Dr. Gregory’s group has shown that improved stem cell retention leads to improved 
outcomes. Previous work has indicated that a stem cell-derived extracellular matrix increases stem 
cell retention in animal models resulting in enhanced bone regeneration [50]. Chapters 2 and 4 
investigate the effect of incorporating this MSC-derived matrix into various tissue engineered 
scaffolds that results in enhanced regeneration. 
1.4.3 MSC Delivery to Bone Defect Sites 
MSCs have been administered through intravenous, intraperitoneal or by local 
administration strategies. However, studies have shown that systemic infusions of MSCs are 
problematic. After systemic infusion >90% MSCs become trapped in the lungs [90, 91] where they 
appear as emboli in afferent blood vessels [92]. The cells in the lungs disappear with a half-life of 
24 hours and trace amounts were recovered in tissues [93]. This suggests that direct implantation 
or injection is a more favorable approach. Therefore it would be of benefit to develop scaffolds 
that could be locally injected to deliver MSCs. Another advantage of injectable grafts is that they 
can match irregular geometries to improve contact between the scaffold and surrounding tissue to 
promote osseointegration. Some bone graft materials are amenable to delivery as microspheres 
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that can be locally injected. For example, hMSCs have been encapsulated in alginate-poly-L-lysine 
[94] and collagen [95] spheres for delivery.
1.5 Summary and Approach 
To address these clinical needs, we propose to develop the methodology to incorporate a 
stem cell-derived extracellular matrix and OEhMSCs into an injectable tissue engineered scaffold. 
We will first create degradable gelatin-based microspheres using a co-flow emulsion device. This 
method is scalable for manufacturing and provides an enhanced surface area to volume ratio to 
allow for more cells and therefore increase extracellular matrix production. hMatrix was deposited 
onto the surface of microspheres by a sacrificial layer of OEhMSCs by culturing with GW9662. 
Finally, fresh OEhMSCs were seeded onto the bioconditioned microspheres to deliver bioactive 
cues to promote osteogenesis. This is the first demonstration of an injectable tissue engineered 
bone graft with the composition and healing capacity of regenerating bone. 
Injectable microspheres incorporating hMatrix and OEhMSCs can advance bone grafting 
procedures by space filling the defect to promote tissue integration, provide osteogenic cues to 
enhance osteogenic differentiation and stem cell retention, and deliver OEhMSCs to stimulate 
bone regeneration. The completion of this project will result in an injectable composite 
microsphere-based scaffold to promote fast and reliable healing of critical sized bone defects. The 
development of a methodology to biomanufacture both an extracellular matrix based graft material 
and cell-based therapeutic would be a major advancement in bone tissue engineering. These 
aspects are expected to have a large impact on bone regeneration and provide new insight into 
future studies of osteogenesis. 
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2. DEVELOPMENT OF SCALABLE MICROSPHERE FABRICATION SYSTEM AND
IN VITRO EVALUATION AS AN INJECTABLE BONE GRAFT MATERIAL 
2.1 Introduction 
 Here we present a manufacturable graft based on naturally-derived biodegradable 
materials that mimics the properties of anabolic bone tissue by utilizing ECM that contains 
collagens VI and XII.  In order to make this process more scalable and reproducible, we utilize a 
cell-scaffold composite where osteogenic cells are cultured on an osteoinductive matrix with high 
surface area to facilitate culture of high cell numbers. As a part of this process, we utilize work 
pioneered from the  Gregory lab at the Institute for Regenerative Medicine at Texas A&M Health 
Science Center demonstrating that inhibiting peroxisome proliferator-activating receptor gamma 
with GW9662, inhibitory crosstalk on the cWnt pathway is released, resulting in a pro-osteogenic 
hMSC phenotype (OEhMSCs) [50]. OEhMSCs maintain classical hMSC-like qualities such as 
immunomodulation and also secrete extracellular matrix (hMatrix) with a composition similar to 
that of anabolic bone. In the initial work, we developed this process to deposit hMatrix onto a 
gelatin sponge in a process referred to as bioconditioning. When hMatrix is utilized to biocondition 
gelatin sponge scaffolds, it stimulates bone formation by human osteoprogenitors in rodent assays 
of femoral healing and in posterolateral lumbar fusion assays [96, 97].  
Orthopedic surgeons are increasingly turning to minimally-invasive surgery in order to 
reduce recovery time, postoperative pain, blood loss, and length of hospital stay [98]. A 
microcarrier scaffold provides a space-filling means of delivering hMatrix into a variety of defect 
geometries. Further, microcarrier culture represents a scalable method to produce hMatrix. This 
motivated our development of injectable microspheres coated with hMatrix to be co-delivered with 
OEhMSCs. Microspheres have been generated using numerous techniques such as manual 
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pipetting of liquid solution into an immiscible phase [95, 99, 100]; emulsification using continuous 
stirring [101-105] and solvent evaporation [106]. The major disadvantages of these methods 
include wide size distributions, as well as laborious, time-consuming procedures that are not 
scalable. The advent of microfabrication technology enabled the use of microfluidic devices to 
produce monodisperse micro-droplets. The most common device designs are a T-junction [107, 
108] and, though less often used, a flow-focusing junction [109] to create discrete droplets using
the shear force between two or more immiscible liquids at their intersection. In this study, coaxial 
flow-focusing nozzles were fabricated with stereo-lithographic (SLA) 3D printing technology 
providing high precision, reproducibility and production rate [110], facilitating scalable production 
of a clinically viable product. 
In the first generation of microspheres, we utilized PEGDA microspheres and incorporated 
natural materials to allow for cell adhesion. However, PEG is biostable within our relevant 
biological timeframe and will not allow room for tissue ingrowth. Therefore, in the second 
generation we used GelMA since it has many features of the native extracellular matrix (ECM), 
including cell adhesive and matrix metalloproteinase-responsive peptide motifs. Tissue 
engineering scaffolds have been made from GelMA using various methodologies, expanding from 
simple molding techniques into bioprinting [37, 111-114], and microfluidic techniques [115-117]. 
Here we demonstrate that microspheres coated with OEhMSC-derived ECM (hMatrix) enhance 
the functionality of osteogenic stem cells by stimulating the secretion of osteogenic and angiogenic 
factors and upregulating osteogenic gene expression. 
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2.2 Materials and Methods 
2.2.1 Collagen and hMatrix functionalization 
Collagen type I contains ~33 lysine groups that enable bioconjugation via the established 
NHS-lysine ε-amino group reaction. Briefly, hMatrix and control rat tail collagen type I were 
reacted with acrylate-PEG-N-hydroxysuccinimide (Acr-PEG-NHS) at molar ratios of 1:1 and 1:10 
relative to their primary amine content. Reactions were performed in 50 mM sodium bicarbonate 
buffer (pH = 10) for 24 hours at 4°C. Excess Acr-PEG-NHS was removed via dialysis 
(MWCO=20,000 Da). Functionalization was confirmed with Fourier transform infrared (FTIR) 
spectroscopy. 
2.2.2 PEGDA Microsphere Fabrication 
 PEGDA (Mw= 8,000 Da) and lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) 
photoinitiator were added to functionalized hMatrix and collagen solutions at 30 wt% and 1 wt% 
and left overnight on a shaker at 4°C. To fabricate the microspheres a pre-mixture of PEGDA 
solution with functionalized proteins and mineral oil were injected with two separate syringe 
pumps. With PEGDA microspheres, we utilize a simple coaxial needle-in-tube junction to produce 
microsphere. At this junction, shear forces from the mineral oil flow periodically separate the 
PEGDA flow into discrete PEGDA microdroplets (Fig. 2.1). A 0.25% concentration of Span 80 
(surfactant) was added to the mineral oil to stabilize droplets of small diameter. Using a serpentine 
path, the droplets flow into the UV light path for a duration of 5 minutes to initiate polymerization 
and collect within the collection beaker. 
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Figure 2.1. (A) Illustration of PEGDA microsphere fabrication. Water-based hydrogels solution and mineral oil are 
pumped through a device that creates isolated microsphere droplets. (B) A detailed view of the nozzle and flow regime. 
2.2.3 GelMA synthesis 
Methacrylation of gelatin was performed as previously reported to obtain GelMA with 80% 
methacrylation [34]. Briefly, type A porcine skin gelatin (Sigma-Aldrich) was mixed at 10% (w/v) 
into Dulbecco’s phosphate buffered saline (DPBS; GIBCO) at 60°C and stirred until fully 
dissolved. Methacrylic anhydride (8% v/v) was added to the gelatin solution at a rate of 0.2 mL/min 
while stirring at 60 °C and then allowed to react for 1 h. Following a 5X dilution with additional 
warm (40 °C) DPBS to stop the reaction, the mixture was dialyzed against distilled water using 
dialysis tubing (10 kDa cutoff) for 1 week at 60 °C to remove salts and unreacted methacrylic acid. 
The solution was lyophilized for 1 week to generate a white porous foam and stored at −80 °C 
until further use. 
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2.2.4 Specialized GelMA Device Fabrication and Microsphere Generation 
After encountering many limitations in size, throughput, and consistency with PEGDA 
microspheres, we developed a more sophisticated device with more controlled geometry to use 
with GelMA microspheres moving forward. The 3D flow-focusing device was fabricated from a 
high heat deflection temperature resin (HTM140 M) using a high-resolution SLA 3D printer 
(EnvisionTEC, Dearborn, MI) as previously described with slight variation [110]. Unlike our 
previous droplet generating devices, the 3D device utilizes a flow-focusing regime and creates 
droplets at the exit orifice, rather than nozzle, with an exit orifice diameter of 250 µm (Fig. 2.2). 
The exit orifice increases the shear stress therefore decreasing the microsphere diameter. 
Figure 2.2. (A) Illustration of 3D printed flow-focusing device. (B) A detailed view of the new flow-focusing regime 
is shown in. (C) A detailed view of the nozzle and exit orifice.  
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GelMA solution consists of 7.5% (w/v) GelMA and 1% (w/v) LAP in PBS. Mineral oil 
was modified with 0.25% (w/v) Span 80 to stabilize droplets to avoid coalescence. At the junction 
of these two coaxial flows, the surface tension and the fluid shear forces from the mineral oil flow 
periodically separate the GelMA flow into discrete microdroplets. The droplets flow into the UV 
light path to activate LAP and thus initiate polymerization. The polymerized microspheres are then 
collected in PBS, washed three times at 3000 rpm for 10 min to remove oil, and stored in PBS at 
4°C until further use. 
2.2.5 Microsphere Injectability 
Microsphere injectability was evaluated by injecting through a 20 AWG needle (ID 0.6 
mm) at a rate of 60 mL/min to simulate conditions expected during injection in the clinic. Samples
were imaged with a microscope and evaluated with ImageJ (NIH) by calculating circularity 
(Eq. 2.1). 




A = area 
P = perimeter 
2.2.6 SEM Imaging 
A scanning electron microscope (SEM, Tescan Vega 3) was used to inspect the surface 
morphology of the bare and bioconditioned microspheres. The microspheres in PBS were injected 
onto a polycarbonate filter holder (Cole-Parmer) containing a Grade 415 filter paper (VWR) to 
remove excess PBS. The microspheres were then sequentially dehydrated using ethanol/water 
mixtures of 5% (v/v) increments up to 100%. The microspheres were finally washed three times 
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with 100% ethanol to remove remaining water. Then, hexamethyldisilazane/ethanol mixtures 
(HMDS, Sigma-Aldrich) of 5% increments up to 100% were used to gradually displace the 
ethanol, followed by three washes with 100% HMDS. The microspheres were left to dry in a 
chemical hood for 96 hours to slowly evaporate the HMDS without collapsing the microspheres. 
2.2.7 hMSC culture 
hMSCs were acquired from Texas A&M Health Science Center adult stem cell distribution 
facility and subcultured according to standard protocols [118]. Briefly, cultures were passaged 
when the cells were approximately 60% confluent. The cells were cultured in Complete Culture 
Media (CCM), consisting of α-MEM (Invitrogen) containing 20% FBS (Atlanta Biologicals), 
4mM L-glutamine (Invitrogen), 100 units/ml penicillin, and 100 µg/ml streptomycin (Hyclone). 
2.2.8 Bioconditioning of microspheres 
hMSCs were combined with microspheres in 10ml of Complete Culture Media (CCM, α-
MEM containing 20% FBS, 4mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml 
streptomycin) in low-adherence 6-well plates and allowed to adhere to the microspheres for 2 
hours with orbital shaking at 20 rpm. To perform rotating suspension culture, cell-laden 
microspheres were transferred to 10-ml Rotating Wall Vessels (RWVs) mounted on a rotation 
controller (Synthecon model RCCS-8DQ)). After 2 days, osteogenic differentiation was induced 
by exchanging the media with Osteogenic Base Media (OBM, CCM containing 5mM β-
glycerophosphate and 50 µg/ml ascorbic acid) supplemented with 10uM GW9662 and the media 
was exchanged every 2 days thereafter over a total of 10 days. The bioconditioned microspheres 
were then processed as previously described for slab scaffolds with slight variation [97]. Briefly, 
the bioconditioned microspheres were washed in excess PBS and decellularized in a lysis buffer 
(PBS containing 0.1% (v/v) Triton X-100, 1mM MgCl2, and 1U/ml DNAse I) for 8 hours at 37°C 
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with orbital shaking at 60 rpm. Decellularized microspheres were washed sequentially in dH2O, 
acetone, and dH2O and then stored in PBS until further use. 
2.2.9 Nano-mechanical testing 
Photo-crosslinked 7.5% GelMA hydrogel cylinders for nano-mechanical testing were 
prepared using 1% LAP as photoinitiator (PI). GelMA solution with PI in aqueous medium was 
placed under vacuum for 30 minutes to remove bubbles. The solution was then inserted into a 
30mm diameter silicone mold and a glass slide was placed on top to provide a flat surface, 
necessary for testing. The solution was then exposed to UV light (10mw/cm2) for 5 minutes to 
form a cylindrical gel 30 mm in diameter and 1 mm thick, and maintained in PBS until Atomic 
Force Microscopy (AFM) testing. The bioconditioned samples were prepared as described above 
in Section 2.2.8. The elastic properties of bare and bioconditioned GelMA hydrogels were 
evaluated with AFM by extracting the elastic modulus from the slope of the force curves (Fig. 2.3, 
between points C and B). 
Figure 2.3. Diagram of AFM force curves. Reprinted from [119]. 
Experiments were performed using a Bioscope System AFM (model 3A, Digital 
Instruments, Santa Barbara, CA) mounted on an Axiovert 100 TV inverted microscope (Zeiss, 
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Thornwood, NY). The Bioscope system is equipped with a Nanoscope IIIa controller and 
Nanoscope III.5.12 software. A special glass holder and protective silicon sleeve allows for 
measurements in aqueous buffer.  The AFM probes used were 5µm borosilicate particles attached 
to silicon nitride cantilevers purchased from Novascan with a 0.01 N/m spring constant. Deflection 
sensitivity was measured for each individual probe. For bioconditioned samples AFM tips were 
incubated in Sigmacote (Sigma-Aldrich, MO) overnight and washed three times with water prior 
to measurements. For each scaffold, 250-750 force curves were sampled and force curves were 
processed in NForceR proprietary software (Trzeciakowski and Meininger, NForceR: nanoscale 
force reader and AFM data analysis package, copyright 2004). The local scaffold stiffness at the 
point of contact was calculated as Young’s modulus of elasticity, by fitting the approach curve 
between the initial point of scaffold contact and point of maximum probe displacement with 
Sneddon’s modified Hertz model [119]. PeakFit software (version 4.11, Systat Software Inc.) was 
used to accurately estimate the peak value and associated confidence intervals for each 
distribution. 
2.2.10 Immunohistochemistry 
Bare microspheres and bioconditioned microspheres were blocked with 5% goat serum 
(MP Biomedicals) and 0.3% Triton X-100 (Sigma Aldrich) for 1 hour at 25°C. Microspheres were 
incubated overnight at 4°C in blocking buffer with rabbit anti-human type VI collagen and rabbit 
anti-human type XII collagen (each 1:200, Novus Biologicals, Littleton, CO). Microspheres were 
washed with PBS and incubated in goat anti-rabbit Fluorescein-conjugated (1:500, Millipore) for 
2 hours at 25°C. Finally, samples were washed in PBS and imaged on an upright confocal 
microscope (Nikon C1 LSC confocal head, Nikon FN1 upright microscope, 20× water-dipping 
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objective, 40-mW Argon ion laser (Melles Griot)). Image stacks were used to produce 3D 
maximum intensity projections. 
2.2.11 Live/dead 
Samples were treated with PBS containing 0.1% BSA (Sigma Aldrich), 1uM calcein AM 
(AnaSpec), and 7.5uM propidium iodide (Sigma Aldrich) for 45 min at 37°C. The microspheres 
were then washed with PBS and stacks of images were collected to produce maximum intensity 
projections. 
2.2.12 ELISA 
Commercially available duoset assay kits for osteoprotegerin (OPG), platelet-derived 
growth factor-AA (PDGF-AA), vascular endothelial growth factor (VEGF), fibroblast growth 
factor (FGF), dickkopf-related protein-1 (Dkk-1), and transforming growth factor beta 1 (TGF beta 
1) were obtained from R&D systems, Minneapolis, MN and performed on conditioned media.
2.2.13 qRT-PCR
The number of hMSCs present on microsphere cultures was measured using qRT-PCR for 
glyceraldehyde-3- phosphate dehydrogenase (GAPDH).  Cells were enumerated by comparison 
with known hMSC standards. Microspheres were subjected to total RNA extraction using a 
commercially available kit (High Pure kit, Roche, Indianapolis, IN). Total RNA was then used to 
make complementary DNA (cDNA) (Superscript III cDNA kit, Invitrogen). Then 6 ng of cDNA 
was amplified in a 20ul reaction containing SYBR Green PCR master mix (Fast SYBR Green, 
Applied Biosystems) on an AriaMx Real-Time PCR System (Agilent Technologies). Collagen and 
BMP2 mRNA expression data was calculated with the 2-CT method using human GAPDH as 
a reference [120]. PCR primers are described in Table 2.1. 
Table 2.1. Primers used in this study. 
30 
Target Sequence 
human GAPDH FOR ctctctgctcctcctgttcgac 
REV tgagcgatgtggctcggct 
human Collagen VI FOR ccatcgtgcgcagcc 
REV tgcgccgactcgtgc 
human Collagen XII FOR cttccattgaggcagaagtt 
REV agacacaagagcagcaatga 
2.3 Results and Discussion 
2.3.1 First generation microspheres based on PEGDA conjugation to functionalized proteins 
One of the most valuable properties of PEG hydrogels is their resistance to protein 
adsorption and cell adhesion which allows controlled introduction of desired bioactive factors. 
Many growth factors and proteins contain lysines which provide a primary amine that can be used 
for functionalization. A widely used method to incorporate proteins into PEG hydrogels is 
functionalization of primary amine-containing proteins with acrylate-PEG-N-hydroxysuccinimide 
(Acr-PEG-NHS) [121-123]. The functionalized proteins can be cross-linked into the PEG 
hydrogels without affecting the bioactivity of these molecules.  FTIR spectra of functionalized 
collagen, (Fig. 2.3) and hMatrix (Fig. 2.4) contained a peak at ~1110 cm-1 corresponding to the C-
O-C of the Acr-PEG-NHS indicating the presence of PEG, and a peak at ~1650 cm-1 corresponding 
to the C=O of the amide linkages of collagen or hMatrix backbone, indicating successful 
conjugation. 
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Figure 2.4. Transmission FTIR spectra of (A) 10% functionalized collagen, (B) 100% functionalized collagen, (C) 
ACR-PEG-NHS, and (D) control collagen. 
Figure 2.5. Transmission FTIR spectra of (A) hMatrix (B) 10% functionalized hMatrix (Acrylate-PEG-hMatrix), and 
(C) ACR-PEG-NHS.
 In this study microspheres were fabricated using PEGDA conjugated to collagen and 
hMatrix to provide a scaffold with tunable cell-material interactions. The impact of reducing 
functionalization of PEG linkers on the collagen backbone and cell adhesion and spreading was 
analyzed with PEGDA-collagen microspheres. An increase in attachment and spreading of hMSCs 
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was observed on PEGDA modified microspheres as percent functionalization of collagen 
decreased (Fig. 2.5).  This observation is consistent with those observed with bioactive hydrogels 
incorporating Scl2-1 proteins and collagen type I [124]. 
Figure 2.6. Cell adhesion and spreading on microspheres incorporating collagen 100% functionalized (A) and 10% 
functionalized (B).  
Microspheres fabricated with 30 wt.% PEGDA, 1 wt.% LAP, and functionalized proteins 
showed good cell viability through 24 hours (Fig. 2.6). LAP photoinitiator was used due to its 
remarkable advantages over I2959 including greater water solubility and increased polymerization 
rates with 365nm wavelength light [125].  However on the microspheres fabricated with PEGDA 
conjugated to functionalized hMatrix, hMSC adhesion was not homogeneously distributed on 
microsphere surface. 
Figure 2.7. hMSCs stained with calcein-AM and propidium iodide seeded on microspheres incorporating collagen 
10% functionalized (A) and hMatrix 10% functionalized (B). 
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For cell differentiation experiments, initial feasibility was demonstrated using collagen 
type I since this is the major component of hMatrix. We functionalized collagen type I (Acrylate-
PEG-Collagen) with photo-cross-linkable groups to enable their incorporation into PEGDA 
microspheres. For qRT-PCR experiments, microsphere samples were cultured in osteogenic 
medium for 8 days with 10µM GW9662 to evaluate the effect of GW9662 treatment on RUNX2 
gene expression. Quantitative RT-PCR demonstrated upregulated transcription of RunX2 between 
OEhMSCs and hMSCs (Fig. 2.7A). Secretion of OPG is also significantly increased upon 
incubation with GW9662 for 4 days compared to the vehicle control (DMSO) (Fig. 2.7B). DMSO 
is considered the vehicle control since GW9662 is dissolved in DMSO. It was determined that this 
method was not optimal for future scale up potential due to the increased volume of hMatrix 
required. Therefore, future work for this study is to repeat these experiments with hMatrix-coated 
microspheres.  
Figure 2.8. (A) RunX2 expression at day 8 normalized to GAPDH expression in response to GW9662 treatment. (B) 
Measurement of OPG secretion by ELISA in response to GW9662 exposure. Values were normalized to cell number. 
* indicates significant differences between groups as determined by ANOVA followed by Student-Neuman–Keuls
post-hoc multiple comparison testing (P<0.05). 
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2.3.2 GelMA microsphere characterization and injectability 
ImageJ software was used to measure the diameter of more than 1000 microspheres to 
obtain the microsphere diameter produced for different flow rate ratios after crosslinking. A target 
microsphere diameter of approximately 100µm was selected to allow for injectability through 
needle gauges ≥27AWG (<210µm), while retaining a high surface area for cell attachment. The 
flow rate ratio of 25 was selected since this led to an average diameter of 87±17μm indicating a 
very uniform distribution (Fig. 2.8A).  Flow rate ratio is defined as the ratio of the flow rate of the 
outer liquid and the inner liquid. 
Injection of microspheres through a 20 AWG needle caused no statistically significant 
impact on sphere circularity (Fig. 2.8C). There was no visible debris or change in sphere 
morphology (Fig. 2.8B). This indicates the microspheres are robust enough to be used in a potential 
clinical setting with no adverse effects on the microsphere shape. 
Figure 2.9. Microsphere Injectability.  (A) Exemplary microspheres before manipulation, (B) after injection through 
a 20 AWG syringe, and (C) Comparison of the circularity of microspheres before and after injecting through a needle 
tip. 
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2.3.3 Bioconditioning of Microspheres 
Microspheres were bioconditioned in a procedure similar to that previously used to 
biocondition a Gelfoam gelatin sponge [50]. Undifferentiated hMSCs (1x104 per cm2) were seeded 
onto the microspheres and allowed to deposit hMatrix over a 10-day period of suspension culture 
in osteogenic media (Fig. 2.9A). The microspheres were then recovered, and the cells removed 
with a gentle procedure (see Section 2.2.8) that avoids harsh solvents or caustic agents in effort to 
maintain the structure of the collagen-rich components of the ECM and also keep the microspheres 
intact. It is important to minimize harsh solvents or caustic chemicals such as NH4OH that may 
denature ECM proteins [126, 127]. SEM micrographs illustrate that the bioconditioned 
microspheres have a fibrillar surface morphology that includes fibrillar bridging (Fig. 2.9C, 
starred) between microspheres and mineralized nodules (Fig. 2.9C, arrowed) in response to 
culture in osteogenic media with GW9662. This indicates that the decellularization procedure is 
gentle and did not disrupt or detach the deposited collagen on the surface. As expected, the bare 
microspheres have a smooth surface (Fig. 2.9B). The bare and bioconditioned microspheres were 
also immunostained for collagens VI and XII since these are unique to OEhMSC derived ECM 
[50]. There is an increase in collagens VI and XII immunostaining on bioconditioned microspheres 
compared to bare microspheres (Fig. 2.9 D and E). This is significant because collagens type VI 
and XII are expressed in relatively high amounts in regenerating bone tissue [13-15]. Studies have 
also shown that collagen VI is essential for normal bone development [128] and collagen XII 
regulates osteoblast polarity and communication during bone formation [129].  
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Figure 2.10. Bioconditioned microsphere validation. (A) Overview of the approach to fabricate bioconditioned 
microspheres. hMSCs were incubated with microspheres for 2 hours then placed in an RWV bioreactor for 10 days 
with OBM+10µM GW9662 replaced every 2 days (2). Microsphere-hMSC constructs were then decellularized as 
previously demonstrated [97]. SEM micrographs of bare (B) and bioconditioned (C) microspheres. (B) Microspheres 
with no hMatrix deposition show a smooth, unaltered surface. (C) Bioconditioned microspheres exhibit an hMatrix 
coating apparent as fibers on the surface and between the microspheres (starred) and mineralized nodules (arrowed). 
Bare (D) and bioconditioned (E) microspheres stained with an antibody against collagen VI and XII.  
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2.3.4 Nano-Mechanical Testing 
Due to the sensitive nature of AFM testing, sample and probe preparation is very important 
to obtain repeatable measurements on each sample. GelMA precursor solution was placed under 
vacuum to remove bubbles that result in sample variability. Additionally, bioconditioned samples 
required AFM tips to be hydrophobically modified with Sigmacote due to the innate stickiness of 
the ECM, which caused the uncoated probes to become stuck to the samples. AFM analysis did 
not reveal a change in elastic modulus between bare and bioconditioned GelMA hydrogels. The 
bare hydrogel data presented an elastic modulus of 1.278 and 4.915 kPa demonstrating a wide 
range in scaffold stiffness. The bioconditioned hydrogel presented an elastic modulus of 1.514 
kPa. With additional confirmation, if there is little or no difference in surface stiffness, this would 
further support that the beneficial effects of bioconditioning are due to the composition of hMatrix. 
Table 2.2. Elastic modulus of bare and bioconditioned hydrogels 
Sample Stiffness (kPa) 
(estimated peak value) 
95% C.I. Number of curves 
Bare sample 1 1.278 1.245-1.311 453 
Bare sample 2 4.915 4.906-4.923 287 
Bioconditioned 
sample 1 
1.514 1.438-1.590 736 
2.3.5 Bioconditioned microspheres increase osteogenic markers 
We speculated that bioconditioned microspheres may also enhance the functionality of 
OEhMSCs in a similar manner to our previous results on bioconditioned gelfoam. Therefore, 
hMSCs were seeded on bare and bioconditioned microspheres and were cultured for 2 days in 
suspension culture to allow cells to proliferate. It is important to note that the bioconditioned 
microspheres have already been seeded with hMSCs, cultured, and then decellularized prior to this 
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step. The samples were then stained with live/dead assay revealing 89% cell viability on bare 
microspheres and 87% cell viability on bioconditioned microspheres (Fig. 2.10).  
Figure 2.11. Live/dead staining of hMSCs present on microspheres demonstrated an abundance of live cells and 
sparsely distributed dead cells. hMSCs were labeled with calcein-AM (green) to visualize live cells and propidium 
iodide (red) to visualize dead cells and seeded on top of bare (A) and bioconditioned (B) microspheres. (C) Cell 
viability 48 hours post seeding is greater than 87% on bare and bioconditioned microspheres. All data presented as 
average ± s.d. All experiments performed in triplicate.   
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Cell proliferation rate was increased on bioconditioned relative to the bare microspheres 
(Fig. 2.11). This implies that the hMatrix deposited on the microspheres promoted early 
proliferation possibly due to the ECM offering additional cell adhesion sites and bioactive factors 
as previously demonstrated [130] . 
Figure 2.12. hMSC proliferation on bare and bioconditioned microspheres. 
For osteogenic experiments, microsphere samples were cultured in osteogenic medium for 
4 days with 10µM GW9662 to evaluate the effect of GW9662 treatment on early stage 
osteogenesis. We examined OPG secretion since OPG inhibits osteoclastogenesis activity. 
Secretion of OPG rose upon incubation of microspheres with GW9662, but reached maximal 
stimulation when OEhMSCs were cultured on bioconditioned microspheres (Fig. 2.12A). PDGF-
AA, which stimulates cell proliferation and is essential for tissue repair, increased with 
bioconditioning treatment although it was not statistically significant (Fig. 2.12B). We also 
quantified angiogenic factors, VEGF and FGF, due to their synergistic effects on bone growth. 
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VEGF secretion significantly increased upon bioconditioning treatment (Fig. 2.12C). FGF 
secretion significantly increased with GW9662 and bioconditioning treatment (Fig. 2.12D). Dkk-
1 has been shown to arrest canonical Wnt signaling during terminal differentiation of 
osteoprogenitor cells [131] [132]. Dkk-1 levels were elevated with GW9662 treatment; however, 
Dkk-1 secretion was significantly reduced with bioconditioning (Fig. 2.12E). Matrix rigidity has 
been shown to regulate Dkk-1 expression with an increase in expression on more compliant gels 
[133]. We hypothesize that this explains increase in Dkk-1 expression with GW9662 treatment 
that conflicts with our previous published results [134]. While our gels are relatively soft, previous 
studies were performed on stiff tissue culture polystyrene dishes, and the potency of the 
bioconditioning process was able to overpower other stimuli. We then examined TGF beta 1 
secretion since TGF beta 1 injections have been shown to promote intramembranous bone 
formation in rat femurs in vivo [135]. Our results demonstrated a significant increase in TGF beta 
1 secretion with bioconditioning treatment (Fig. 2.12F). This corresponds with our previous work 
demonstrating that hMatrix stimulates cells to secrete osteogenic and angiogenic ligands [50, 97]. 
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Figure 2.13. Bioconditioning enhances osteogenic and angiogenic growth factor secretion. OPG (A), PDGF-AA (B), 
VEGF (C), FGF (D), Dkk-1 (E), and TGF beta 1 (F) secretion was measured from the medium by ELISA. Values 
were normalized to cell number. Statistics are (n=3) one sided ANOVA and Tukey post‐test *, **represents p<0.05, 
0.01. All data presented as average ± s.d. All experiments performed in triplicate.  
We have previously demonstrated that bioconditioned gelfoam stimulates the expression 
of osteogenic factors by OEhMSCs, indicating a similar effect may be achieved with 
bioconditioned microspheres [97]. This data demonstrated an upregulation of collagen types VI 
and XII in OEhMSCs compared to hMSCs (Fig. 2.13 A and B). To examine if these developmental 
collagens stimulate the expression of osteogenic factors, OEhMSCs were then seeded onto bare 
and bioconditioned microspheres. The data suggested that bioconditioned microspheres induced 
the expression of BMP2, which is important due to its important role in osteogenesis and bone 
repair (Fig. 2.13C). This is similar to our previous findings of highly upregulated BMP2 on 
bioconditioned gelfoam compared with gelfoam alone [97]. Integrin activation and MAPK 
signaling have been shown to induce BMP2 expression and osteogenesis [136]. Therefore, the 
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collagens VI and XII in the bioconditioned microspheres may increase BMP2 expression in 
OEhMSCs and hMSCs, which has been shown to enhanced bone regeneration in vivo [137]. 
Figure 2.14. Bioconditioned microspheres upregulate BMP2 gene expression. Quantitative PCR demonstrating 
upregulated transcription of collagen VI (A) and collagen XII (B) with 10uM GW9662 treatment. (C) BMP2 gene 
expression is also upregulated with GW9662 treatment and bioconditioning. Data is presented as fold change in 
transcription between samples and monolayer hMSCs in cell culture media. Statistics are (n=3) one sided ANOVA 
and Tukey post‐test **represents p<0.005. All data presented as average ± s.d. All experiments performed in triplicate. 
2.4 Conclusion 
We developed PEGDA microspheres conjugated to functionalized hMatrix. However since 
a lot of hMatrix material was needed for encapsulation, we thought it would be more feasible to 
coat the microspheres. Also, this PEGDA microsphere fabrication method did not allow for 
microsphere diameter tunability and high throughput fabrication. Therefore, we have successfully 
created a system to produce biodegradable GelMA microspheres of tunable, monodisperse size. 
After evaluating multiple methods to incorporate hMatrix, we have determined bioconditioning 
the surface of these microspheres is the most feasible for optimizing cell culture and throughput. 
In this study, we show that bioconditioned GelMA microspheres contain collagens VI and XII, 
which has previously been shown to provide an extracellular microenvironment that mimics 
43 
repairing rather than homeostatic bone tissue. We also demonstrate that bioconditioned 
microspheres stimulate the secretion of osteogenic and angiogenic factors and upregulate the gene 
expression of BMP2. Motivated by these positive in vitro results, the hMatrix/OEhMSC composite 
microspheres were evaluated for their ability to regenerate mice calvarial and long bone defects, 
in vivo, in Chapter 3.  
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3. IN VIVO EVALUATION OF BIOCONDITIONED MICROSPHERES AS A BONE
GRAFT MATERIAL 
3.1 Introduction 
Previous work from Clough et al. [96, 97] demonstrated a process to biocondition gelatin 
sponges, resulting in a layer of deposited hMatrix. hMatrix was shown to stimulate bone formation 
with human osteoprogenitors in rodent assays of femoral healing and in posterolateral lumbar 
fusion assays [96, 97]. However, injectable delivery is desirable to allow space-filling of defects 
and formation of a continuous interface with existing bone. In Chapter 2, we to fabricate and 
characterize GelMA microspheres. We then cultured and characterized OEhMSCs and their 
secreted matrix (hMatrix) on these microspheres and confirmed the presence of hMatrix 
components, collagens VI and XII, with immunostaining. We also demonstrated that OEhMSC 
attachment to the hMatrix-coated microspheres stimulates the secretion of osteogenic and 
angiogenic factors and upregulates BMP-2 gene expression. In this chapter, we describe the 
evaluation of the regenerative capacity of bioconditioned microspheres in vivo. Intramembranous 
and endochondral bone repair were assessed with calvarial and pin-stabilized femoral defect 
models, respectively. 
Herein, we demonstrate that bioconditioned microspheres enhance bone regeneration in 
murine calvarial and femoral defect models compared to bare microspheres. With the addition of 
OEhMSCs, bioconditioned microspheres resulted in bone regeneration comparable to that induced 
by the current gold standard of BMP2 delivered from a collagen sponge. These results indicate the 
hMatrix-coated microspheres are effective vectors for delivery of stem cells for bone regeneration 
with potential to replace the need for autografts. 
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3.2 Materials and Methods 
3.2.1 Calvarial defect model 
Studies were performed in accordance with an institutionally approved animal use protocol 
as described previously [50, 134]. Briefly, a 4 mm diameter circular full-thickness calvarial defect 
was generated in 2-month-old immunocompromised nude mice, followed by administration of 50 
µL (settled volume) of microspheres, with or without 2 million OEhMSCs, suspended in a mixture 
of 25 µL thromboplastin and 25 µL reconstituted human plasma. After the plasma clotted in situ, 
the scalp was closed by suture and defects healed for 4 weeks. Mice were then humanely 
euthanized and calvarial bones were carefully dissected with a dental cutting wheel. Digital x-rays 
were collected and analyzed by densitometry as described previously [50]. A relative healing index 
(RHI) was calculated, where a value of 1 represents radioopacity equivalent to the contralateral 
side and 0 is equivalent to air. These same calvarial specimens were then fixed and prepared for 
histology. 
3.2.2 Femoral defect model 
Studies were performed in accordance with an institutionally approved animal use 
protocol. A 3 mm-long pin-stabilized defect was generated in 2 month-old immunocompromised 
nude mice as described previously [97, 138] in accordance with institutionally approved protocols. 
25 µL (settled volume) of microspheres, with or without 1.8 million OEhMSCs, were suspended 
in a mixture of 20 µL of thromboplastin and 20 µL reconstituted human plasma. The entire mixture 
was administered adjactent to the pin and held in place by carefully closing the muscle and skin 
layers by suture. After 5 weeks of healing, mice were humanely euthanized and hind-limbs were 
fixed in buffered formalin. Femurs were scanned using a Skyscan1275 micro-computed 
tomography (µCT) scanner (Bruker, Belgium) as described [138]. Because significant bone 
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formation was observed at the site of the defect and at distal sites, measurements of bone volume 
and surface-to-volume ratios were calculated for the entire femora using CTAnal software 
(Bruker).   
3.2.3 Histology 
Standard histology was performed on decalcified, paraffin-embedded specimens as described 
previously [50, 97].  Briefly, samples were harvested and fixed at 4°C until decalcification. 
Samples were then washed with PBS and placed in 1 M dibasic ethylenediaminetetraacetic acid 
(EDTA), pH 8.0 (Sigma Aldrich, St. Louis, MO). Solution was changed every 2 days until samples 
were radiolucent. Samples were then sequentially dehydrated with ascending gradients of ethanol, 
cleared with Sub-X clearing agent (Surgipath Medical Industries, Inc), and infiltrated with paraffin 
wax. Calvarial sections were made in the sagittal plane and femoral sections were made axially 
after removal of the pin. Paraffin-embedded samples were cut in 10 to 15 µm sections and floated 
onto microscope slides, baked at 60°C for 1 h, deparaffinized with citrus clearing agent (Richard-
Allan Scientific), and rehydrated with distilled water. Samples were stained with hematoxylin 
solution Gill No.3 (Sigma Aldrich, St. Louis, MO), rinsed with distilled H2O, counterstained with 
eosin Y 1% (w/v) solution in water (ACROS), dehydrated, and cleared. Masson’s trichrome 
staining was performed using a commercially available kit (American Mastertech Scientific Inc., 
Lodi, CA, USA). Cover slips were mounted using Permount with toluene (Fisher Scientific). 
Images were taken using an upright microscope (Nikon Eclipse 80i fitted with a Retiga 2000 
camera).  
3.2.4 Statistical Analysis 
Statistical tests and data plotting were performed with GraphPad Prism version 7.00 for 
Windows. Specifically, a two-tailed t-test was used to determine statistical significance, assuming 
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unequal sample variance for each experimental group when comparing individual groups. For 
multiple tests of means within data sets, data was statistically analyzed by one-way analysis of 
variance (ANOVA) and post-analyzed by Tukey’s method.  
3.3 Results 
3.3.1 Bone healing by bioconditioned microspheres and OEhMSCs in a murine calvarial 
defect model 
To determine whether the bioconditioned microspheres were capable of functioning as a 
bioactive vehicle for OEhMSCs during intramembranous bone repair, we employed a calvarial 
defect model in mice we have described previously [50, 134]. Bioconditioned or bare microspheres 
were delivered, with or without OEhMSCs, into circular full-thickness calvarial defects. Imaging 
and quantification of healing by densiometry indicated that after 4 weeks bioconditioned 
microspheres resulted in increased healing relative to mock negative controls although it was not 
statistically significant (Fig. 3.1B). When OEhMSCs were delivered with bare microspheres, there 
was a statistical increase in healing compared to mock controls. However, when OEhMSCs were 
delivered with bioconditioned microspheres, healing was significantly increased to levels 
equivalent to or better than BMP2 controls (Fig. 3.1B).  Collectively, the data indicated that 
OEhMSCs and bioconditioning synergistically enhance calvarial healing to an extent as good as 
or better than the clinical standard.  
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Figure 3.1. Bone healing by OEhMSCs and bioconditioned microspheres in a murine calvarial lesion model. (A) 
Representative digital radiographs used to generate data. (B) RHI values after 4 weeks of healing are shown where a 
value of 0 represents no healing and 1 represents healing equivalent to the contralateral side. Negative controls (Mock), 
hMatrix-coated (Bioconditioned) and uncoated microspheres (Bare) were administered without OEhMSCs. The 
positive control consisting of 50 µg BMP2 on a gelfoam sponge (BMP2) was also administered without OEhMSCs. 
Statistics: n=4, analyzed by ANOVA and Tukey post-test: *p<0.05, **p<0.01, ***p<0.005.  
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The calvarial defects that received bioconditioned microspheres with OEhMSCs show an 
intermediate level of opacity indicating the formation of immature bone (Fig. 3.1A). To confirm 
this observation, histological staining was performed on the same samples used for densiometry.  
The histological staining results agreed with the densiometry results; bioconditioned microspheres 
administered with OEhMSCs generated a significant amount of immature bone at the defect site 
indicated by the dark blue staining (Fig. 3.2 D and J). Calvaria that received bare microspheres 
with OEhMSCs also resulted in the formation of immature bone, however, the bone was not as 
compact (Fig. 3.2 C and I). Microspheres alone (Fig. 3.2 A, B, G, and H) stimulated the generation 
of fibrous tissue, but bone formation was not evident. Mock defects (Fig. 3.2 E and K) resulted in 
a thin fibrotic scar with very little new tissue. Controls that received BMP2 formed numerous 
diffusely distributed isolates of immature bone tissue in between patches of gelatin foam (Fig. 3.2 
F and L). These results confirm the synergistic effects of bioconditioned microspheres and 
OEhMSCs on intermembranous bone repair.  
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Figure 3.2. Histology of calvarial defects treated with microspheres and OEhMSCs. Low (A-F) and medium (G-L) 
power micrograph of sagittal sections of calvarial at defect midpoint.  for bare microspheres (A, G), bioconditioned 
microspheres (B, H), bare microspheres with OEhMSCs (C, I), bioconditioned microspheres with OEhMSCs (D, J), 
mock defect receiving no cells or microspheres (E, K), positive control receiving 50 g BMP2 on gelatin foam (F,L. 
Scalebars are 150 m (A-F) and 75 m G-L). Paraffin sections were stained with Masson’s Trichrome. 
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3.3.2  Bone healing by bioconditioned microspheres and OEhMSCs in a murine femoral defect model 
To determine whether the bioconditioned microspheres were capable of functioning as a 
bioactive vehicle for OEhMSCs during endochondral bone repair, we employed a pin-stabilized 
femoral defect model in mice [97, 138]. Qualitative observation of µCT scans indicated minimal 
signs of healing after 5 weeks of healing in cases where bare microspheres were administered with 
or without cells (Fig. 3.3A and C). A small amount of bone formation was observed when 
bioconditioned microspheres were administered without cells (Fig. 3.3B). In contrast, significant 
bone formation was observed with femora that received bioconditioned microspheres with 
OEhMSCs (Fig. 3.3D). Unexpectedly, extensive bone growth could be observed not only at the 
defect site, but also throughout the femora at distal sites too, suggesting that the bioconditioned 
microspheres and cells had distributed themselves along the axis of the bone and their 
osteoanabolic activity was not confined to the defect (Fig. 3.3G). Therefore, for samples consisting 
of bioconditioned microspheres and cells, the volume of the entire femur was measured for each 
sample to more accurately quantify the impact. Measurements confirmed qualitative observations 
in that femora that received bioconditioned microspheres and cells had significantly more repaired 
femur volume compared to other groups (Fig. 3.3E). Bone surface to volume ratio is an indicator 
of de novo bone compactness and can be extrapolated as an indicator of bone strength. The 
bioconditioned microsphere and/or OEhMSC groups exhibited greater bone compactness 
compared to groups treated with bare microspheres only (Fig. 3.3F). These data confirmed that 
bioconditioned microspheres are also advantageous for stimulation of bone formation in murine 
femora. 
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Figure 3.3. Stimulation of bone formation by bioconditioned microspheres and OEhMSCs in a murine critical femoral 
defect model. (A-D) Micro-CT-generated orthogonal images and x-ray scans. (G) In bottom right, close-up of partial 
bridging (arrowed) seen with bioconditioned microspheres with OEhMSCs. (E) Whole femur volume (F) and surface-
to-volume ratio as measured by µCT.  Bioconditioned microspheres administered with OEhMSCs generated more 
bone than other conditions. Data indicate that defects receiving bioconditioned microspheres and/or OEhMSCs 
exhibited greater bone compactness than those that received bare microspheres. Statistics: n=6-7, analyzed by 
ANOVA with Tukey post-test. *=p<0.05, **=p<0.01, ***=p<0.005.  
53 
The femoral defects that received bioconditioned microspheres with OEhMSCs showed an 
increase in bone density around the collar indicating bone regeneration (Fig. 3.3D). To confirm 
this observation, histological staining was performed on the same samples used for µCT. The 
histological staining results agreed with the µCT results; bioconditioned microspheres 
administered with OEhMSCs generated a significant amount of de novo bone at the defect site 
indicated by the dark blue staining. These samples displayed a spongy appearance, suggesting the 
formation of a trabecular network (Fig. 3.4 D, J, and K) and signs of both osteoblast (Fig 3.4L, 
arrowed) and osteoclast (Fig. 3.4L, starred) activity. Bare microspheres had negligible healing 
effects on bone (Fig. 3.4A) but bioconditioned microspheres alone appeared to induce the 
formation of a thin layer of compact, cortical-like bone tissue, as indicated by the dense 
organization and dark blue staining, with no sign of trabecular structures and minimal cellularity, 
(Fig. 3.4 B, E, and F). Bare microspheres with OEhMSCs formed tissue with a high degree of 
cellularity (Fig. 3.4I), fibrotic deposits and diffuse signs of bone formation (Fig. 3.4 C, G, and H). 
These results confirm the synergistic effects of bioconditioned microspheres and OEhMSCs on 
endochondral bone repair.  
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Figure 3.4.  Histology of axial sections of femurs at defect midpoints, treated with microspheres and OEhMSCs. (A-
D) Low power micrograph (4x, bar=250 µm). (E, G, J) Mid-power micrographs (10x, bar=100 µm). (F, H, I, K, L) 
High-power micrographs (20x, bar=25 µm). (A) Bare microspheres, (B, E, F) bioconditioned microspheres, (C, G, H, 
I) bare microspheres with OEhMSCs, (D, J, K, L) bioconditioned microspheres with OEhMSCs. I and L stained with
hematoxylin and eosin, all others stained with Masson’s trichrome. 
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3.4 Discussion 
A previous study by Tour et al. evaluated the bone healing properties of hydroxyapatite 
microparticles combined with an extracellular matrix (ECM) derived from osteoblasts [139]. The 
administration of hydroxyapatite microparticles with ECM resulted in significantly increased 
calvarial repair compared to hydroxyapatite alone. However, the hydroxyapatite microparticles 
with ECM revealed significantly increased number of macrophages and foreign body giant cells 
found at the defect compared with hydroxyapatite alone indicating an inflammatory response. 
Wang et al. [140] also developed micro-sized tissue engineered bone grafts using demineralized 
bone matrix (DBM) microcarriers to administer mesenchymal stem cells. When implanted 
ectopically, these constructs achieved almost complete healing of a critical size calvarial defect at 
3 months.  While this method led to substantial regeneration, DBM is limited by batch variability 
and a risk of immunogenicity [141].. In our approach, scaffolds are bioconditioned with cells from 
a source that is thoroughly screened for infectious diseases, and fully decellularized, while 
retaining the crucial active components of the ECM to encourage healing. We attribute the 
enhanced regeneration of our bioconditioned scaffolds to the similar composition to anabolic bone 
tissue and the degradability of the gelatinous scaffold, which allows room for tissue ingrowth. 
This study shows that bioconditioned microspheres provide a biologically complex 
extracellular microenvironment that mimics components of anabolic bone tissue in contrast to 
available alternatives such cadaveric bone and ceramics. When mixed with a source of 
osteoprogenitor cells, these microspheres are able to stimulate bone formation in rodent assays of 
craniofacial healing to an extent comparable to the gold standard BMP2 collagen sponge. 
Bioconditioned GelMA represents a novel material with osteogenic efficacy surpassing BMP2 
without the associated inherent disadvantages. Our strategy mimics bone grafts in terms of 
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composition and function, but avoids the morbidity associated with a secondary surgical procedure 
in autografts.  
One limitation of this study is that the animals were not immunocompetent; therefore, the 
capacity of bioconditioned microspheres to evade immune rejection was not evaluated. ECM 
proteins, including type I collagen, stimulate both humoral and cell-mediated responses. However, 
many immunologically unrelated extracellular matrix products (even xenografts) do not elicit 
substantial immune responses and we expect the same for bioconditioned microspheres. We 
speculate that hMSCs and, specifically, their deposited ECM do not require an autologous cell 
source given their limited immunogenicity in allogenic recipients.  
3.5 Conclusion 
In conclusion, we have successfully created a novel bone graft material consisting of a 
composite of bioconditioned GelMA microspheres with OEhMSCs. These studies show that 
bioconditioned microspheres serve as a promising scaffold for intramembranous and endochondral 
bone repair when combined with OEhMSCs for calvarial and long bone healing. The enhanced 
regenerative capacity of hMatrix/OEhMSCs composite microspheres may satisfy the need in 
orthopedic medicine for patient populations with traditionally poor bone healing such as the elderly 
or patients with osteoporosis. In the future the bioconditioned microspheres may also be evaluated 
as carriers for other cells types to regenerate other tissues such as cartilage.  
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4. PATIENT-SPECIFIC FABRICATION OF BIOCONDITIONED,
CRANIOMAXILLOFACIAL BONE GRAFTS 
4.1 Introduction 
Approximately 200,000 craniomaxillofacial (CMF) injuries occur annually due to a variety 
of causes, including trauma, congenital malformations, neoplasia and neurosurgical interventions. 
Complex cases require repair by cranioplasty to protect intracranial contents, reestablish 
anatomical boundaries between intra and extra-cranial structures, restore aesthetic craniofacial 
contour, and support craniofacial soft tissues. The current gold standard for CMF repair is the 
autologous vascularized free fibular flap; however, this technique relies on a limited source of 
donor tissue, incurs donor-site morbidity and the complex geometries of bone within the CMF 
region cannot be easily recapitulated using fibular segments [142]. Custom-shaped alloplastic 
implants have been investigated, including acrylics and titanium, but have their limitations such 
as tissue necrosis and stress shielding [143, 144]. Additive manufacturing of biomaterial constructs 
has shown high potential for fabrication of CMF implants to promote osteogenesis. Recently, 
hydroxyapatite [145] and decellularized trabecular bone particles [146] have been blended with 
PCL for 3D printing of osteogenic scaffolds for craniofacial regeneration.  
When using hMSCs to produce hMatrix, new donor sources must be identified when cell 
banks become exhausted, and replacement hMSC cell banks must be re-validated to establish 
efficacy and safety. To address these limitations, hMSCs have been derived from human induced 
pluripotent cells (iP-hMSCs) [147]. Unlike hMSCs, undifferentiated iP-hMSCs divide without 
senescence, providing a theoretically limitless supply of reproducible biomaterial for the 
production of iP-hMSCs. Therefore, batches of hMatrix can be generated in theoretically limitless 
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numbers from a genetically identical source of iP-hMSCs in a reproducible manner, effectively 
dismissing the need for variable donor-derived biomaterial.  
Advanced bioinks, involving strategies including interpenetrating polymer networks 
(IPNs) and nanomaterials, have recently been developed to provide both cytocompatability and 
excellent printing properties [148]. Nanoengineered Ionic-Covalent Entanglement (NICE) 
networks employs nanosilicates (nSi) and ionic covalent entanglement (ICE) networks to reinforce 
the mechanical properties of the hydrogels to strengthen gelatin hydrogels. nSi have a high 
capacity to form reversible non-covalent bonds with polymers due to their dicotic surface charge 
and extremely high surface area to volume ratio. The addition of nSil to Gelatin Methacrylate 
(GelMA) improves the mechanical properties and the osteogenic potential of GelMA hydrogels 
[44]. ICE networks are a subset of IPNs in which one hydrogel is crosslinked via ionic interactions 
and the other by covalent crosslinks [149, 150]. This results in high strength and toughness under 
mechanical loading due to energy dissipation through reversible disruption of crosslinks within 
the ionically crosslinked network, while the more flexible covalently-crosslinked network remains 
intact. Preliminary results demonstrate that addition of nSi to GelMA/κCA hydrogels results in 
improved printability and an overall stiffer hydrogel [148]. However, while NICE provides the 
necessary binding domains for cell attachment and nSi-GelMA nanocomposites exhibit osteogenic 
properties (Xavier at al.), NICE fails to mimic the complex microenvironment of healing bone. 
The goal of the present work was to demonstrate the application of NICE bioink for 
creating standalone CMF bone grafts with precise geometries and that bioconditioning enhances 
the osteogenic properties of NICE. Further, we coated NICE scaffolds with a scalable source of 
hMatrix. The bioconditioned scaffolds were decellularized and their capacity to enhance in vitro 
osteogenic differentiation of newly seeded bone marrow hMSCs was evaluated.  
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4.2  Materials and Methods 
4.2.1 NICE bioink 
Methacrylation of gelatin was performed using a previously reported method to obtain 
gelatin methacrylate (GelMA) with 80% methacrylation [34]. Kappa-carrageenan (κCA) was 
obtained from TCI America (USA). Nanosilicates (Laponite XLG) were obtained from BYK 
Additives Inc. The NICE bioink (10% w/v GelMA, 1% w/v κCA, 2% w/v nanosilicates, and 0.25% 
w/v Irgacure 2959) was obtained by 1:1 mixing of 20% w/v GelMA, 2% w/v κCA, and 0.5% w/v 
Irgacure 2959 with a solution of 4% w/v nanosilicates. The solution was vortexed and subsequently 
sonicated for 2 minutes to ensure homogenous dispersion of components. Solutions were stored 
overnight at 40°C. 
4.2.2 Bioprinting 
Representative bone defects were extracted from a model of a human skull by making 
multiple cuts and selecting segmented portions (thingiverse.com, thing: 518109). The skull model, 
with those defects subtracted, was then printed at 1:2 scale in ABSplus on a Mojo extrusion-based 
3D printer (P430 material, Stratasys, Inc., Eden Prairie, MN). STL files were loaded into Slic3r to 
customize printing options and converted into G-code printer instructions. Relevant printing 
parameters include the infill density (100%), layer height (200 µm), extrusion width (600 µm), 
and print speed (20 mm/s) for printing and travel moves. The open source user interface, or “host”, 
Pronterface (https://github.com/kliment/Printrun) was utilized to control the 3D printer. The bioink 
was stored at 37 °C and loaded into an extrusion tube with a 400µm nozzle tip and extrusion 
printed through a RepRap Prusa i3-style printer. Using these settings, a 30mm diameter x 0.6mm 
disk was printed. The disk scaffold was covalently crosslinked via exposure to 25 mW/cm2 365nm 
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UV light for 80 seconds. Ionic crosslinking was completed by submersion in 5% potassium 
chloride (KCl) for 15 minutes. 
4.2.3 Generation of iP-hMSCs 
iP-hMSCs (kindly provided by Dr. Fei Liu) were generated as described previously [147]. 
Figure 4.1. Schematic elucidating the development of bioconditioned NICE scaffolds. The iP-hMSCs were seeded on 
NICE scaffolds and cultured in the presence of GW9662 for 10 days followed by decellularization. The scaffolds 
modified with iP-hMSC-derived ECM were seeded with hMSCs and evaluated in vitro for osteogenic differentiation. 
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4.2.4 Bioconditioning of 3D printed scaffolds 
3D printed scaffolds were bioconditioned in a 4 step process (Fig. 4.1). iP-hMSCs were 
incubated in 10ml of Complete Culture Media (CCM), consisting of α-MEM (Invitrogen) 
containing 20% FBS (Atlanta Biologicals), 4mM L-glutamine (Invitrogen), 100 units/ml 
penicillin, and 100 µg/ml streptomycin (Hyclone) in low-adherence tissue culture plates with 
NICE scaffolds at density of 10,000 cells/cm2. Cells were allowed to adhere for 2 hours with orbital 
shaking at 20 rpm. After 2 days, the type of culture media was changed to Osteogenic Base Media 
(OBM, CCM containing 5mM β-glycerophosphate (Calibiochem) and 50 µg/ml ascorbic acid 
(Sigma)) supplemented with 10 µM GW9662 and changed every 2 days thereafter for 10 days. 
NICE scaffolds were then processed following a decellularization protocol previously described 
with slight variation [97]. Briefly, the NICE-iP-hMSC scaffolds were washed in excess PBS and 
decellularized by lysis in buffer consisting of PBS containing 0.1% (v/v) Triton X-100 (Sigma), 
1mM MgCl2 (Thermo Fisher), and 1U/ml DNAse I (Thermo Fisher) for 8 hours at 37°C with 
orbital shaking at 60 rpm. The decellularized scaffolds were washed in dH2O, acetone, and dH2O. 
Lastly, the scaffolds were swelled in PBS until further use. The processed scaffolds were hereafter 
referred to as bioconditioned NICE, whereas NICE scaffolds lacking the iP-hMSCs derived matrix 
were referred to as bare NICE. 
4.2.5 BM-hMSC Cell Culture 
BM-hMSCs were cultured in both bare and bioconditioned NICE scaffolds in a similar 
fashion as used for iP-hMSCs. Briefly, BM-hMSCs were seeded at a density of 10,000 cells/cm2 
in CCM in low-adherence 6 well plates for 2 days. The BM-hMSCs/scaffolds were then cultured 
for an additional 8 or 21 days in OBM supplemented with 10 µM of GW9662, with media changes 
occurring every 2-3 days. 
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4.2.6 Immunohistochemistry 
Scaffolds were blocked with 5% goat serum (MP Biomedicals) and 0.3% Triton X-100 
(Sigma Aldrich) for 1 hour at 25°C. Rabbit anti-human type VI collagen (Novus Biologicals, 
Littleton, CO) and rabbit anti-human type XII collagen (Novus) primary polyclonal antibodies 
were diluted 1:200 in the blocking buffer and added overnight at 4°C. Samples were washed with 
PBS before addition of goat anti-rabbit Fluorescein-conjugated secondary antibody (1:500, 
Millipore) for 2 hours at 25°C. Finally, samples were washed in PBS and imaged on an upright 
confocal microscope (Nikon D Eclipse C1).  
4.2.7 Live/dead 
hMSCs were seeded onto scaffolds for 48 hours in CCM. Samples were then treated with 
PBS containing 0.1% BSA (Sigma Aldrich), 1µM calcein AM (AnaSpec), and 7.5µM propidium 
iodide (Sigma Aldrich) for 45 min at 37°C. The scaffolds were then washed with PBS and images 
were collected using an upright confocal microscope (Nikon D Eclipse C1). Quantitative confocal 
microscopy results were obtained by loading images into ImageJ. The Cell Counter plug‐in was 
used to mark cells manually to obtain a total live count (green fluorescence) and dead count (red 
fluorescence). At least 500 cells were scored per sample. 
4.2.8 Calcium content 
The calcium content was measured using an o-Cresolphthalein-Calcium reaction assay 
(Cayman Chemicals) after 21 days of culture. Briefly, 5 mm biopsies were taken from 8 cm 
hydrogels and were fixed overnight at 4⁰ C in 4% formaldehyde. Samples were then washed three 
times with PBS before being dried overnight in a desiccator. Calcium was extracted from dried 
samples by undergoing an overnight acidic digestion at 4⁰ C using 0.5 M HCl on a tube rotator. 
Samples were centrifuged prior to collecting the supernatant for downstream use. 
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4.2.9 qRT-PCR 
After 8 and 21 days of culture, total RNA was extracted from the hydrogels via a modified 
protocol using a total RNA isolation kit (High Pure, Roche). Cells were separated from the 
hydrogels by brief trypsinization and centrifugation before treatment with RNA extraction buffer. 
The purity (A260/A280~2.0) and concentration of isolated RNA was quantified before being used 
for cDNA synthesis in 21 µL reaction (Superscript II kit, Invitrogen). Approximately 8 ng of 
cDNA was amplified in a 20 µL reaction with Brilliant III Ultra-Fast SYBR Green QPCR Master 
Mix with Low ROX (Agilent) on an Agilent Aria Mx Real-Time PCR System. Primer sequences 
used can be found in Table 1. Relative gene expression was calculated via ∆∆CT method, using 
uninduced hMSC monolayer cultures on tissue culture polystyrene for either 8 or 21 days in CCM 
as a control. 
Table 4.1. Primers used in this study. 
Target Sequence 
human GAPDH FOR ctctctgctcctcctgttcgac 
REV tgagcgatgtggctcggct 
human Collagen VI FOR ccatcgtgcgcagcc 
REV tgcgccgactcgtgc 
human Collagen XII FOR cttccattgaggcagaagtt 
REV agacacaagagcagcaatga 
human BMP2 FOR cccagcgtgaaaagagagac 
REV gagaccgcagtccgtctaag 
human OCN FOR tcacactcctcgccctattg 
REV ctcttcactacctcgctgcc 
human OPN FOR catcacctgtgccataccagtt 
REV ttggaagggtctgtggggcta 
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4.2.10 Statistical analysis 
Statistical tests and data plotting were performed with GraphPad Prism version 7.00 for 
Windows. Specifically, two-tailed t-test was used to determine statistical significance, assuming 
unequal sample variance for each experimental group when comparing individual groups.  
4.3  Results 
4.3.1 3D printing NICE scaffolds for CMF defects 
 We previously demonstrated that large, free-standing tubular structures could be printed 
with NICE [148] . To validate the potential of bioconditioned NICE scaffolds for treating CMF 
defects, we further assessed the ability of NICE to be printed into anatomically relevant shapes 
for CMF repair. Figure 4.2 shows the full 3D printing workflow with each defect highlighted. 
The isolated model, G-code representation, and actual printed construct demonstrate print 
fidelity. The NICE bioink was also mixed with FITC to demonstrate high filament print fidelity 
as shown in the representative confocal image (Fig. 4.2M). Note that the FITC scaffolds were 
printed at a lower infill density. The printed NICE scaffolds were easily handled with forceps 
and press-fit into the complementary skull defects with minimal effort (Fig. 4.3). A stainless-
steel mesh was added and secured with miniature screws to emulate how these constructs could 
be used in a surgical setting. 
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Figure 4.2. NICE bioinks reproduce various anatomical defects with high print fidelity. NICE bioink can be used to 
print human craniomaxillofacial defects. The SolidWorks file of each defect (A, D, G, J) was sliced using Slic3r v1.1.7 
(B, E, H, K) and printed with a custom-built RepRap Prusa i3-style 3D printer resulting in 3D printed jaw bone (L), 
eye socket (F), cheek bone (I), and parietal bone (C) highlighting the high print fidelity between models and printed 
structures. Confocal microscopy of representative filaments within printed NICE scaffolds at 10% infill density 
obtained by mixing NICE bioink with FITC (M).  
Figure 4.3. Clinically relevant implementation of 3D printed NICE bioinks. Human skull was 3D printed (A) and the 
jaw bone, eye socket, cheek bone, and parietal bone defects were inserted into the skull (B) demonstrating 3D printing 
of patient specific craniomaxillofacial defects. For the parietal and jaw bones surgical stainless steel mesh was screwed 
into the skull (C) to help keep the scaffolds in place. 
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4.3.2 Characterization of 3D printed bioconditioned scaffolds  
 We previously demonstrated that ECM (hMatrix) derived from osteogenically enhanced 
bone marrow-derived hMSCs (OEhMSCs) co-delivered with fresh OE-hMSCs enhances cell 
retention to result in accelerated bone repair in vivo [50]. The bioconditioning process 
illustrates the deposition of hMatrix onto the 3D printed scaffolds (Fig. 4.1). To evaluate 
hMatrix deposition onto 3D printed NICE scaffolds, 1x104 iP-hMSCs per cm2 were cultured in 
the presence of GW9662 and seeded onto the planar scaffolds to deposit ECM over a 10-day 
period. The ECM was decellularized using a lysis buffer consisting of Triton X-100, MgCl2, 
and DNAse I. The presence of hMatrix was assessed by immunostaining for collagens VI and 
XII, which are highly expressed by OEhMSC as they generate hMatrix [97]. There was an 
increase in collagens VI and XII immunostaining on bioconditioned scaffolds compared to bare 
scaffolds (Fig. 4.4).  
Figure 4.4. Bioconditioning of printed NICE scaffolds results in deposition of collagens VI and XII. Bare (A, C) and 
bioconditioned (B, D) scaffolds were stained with antibodies against collagen VI (A, B) and collagen XII (C, D).  
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4.3.3 Bioconditioned scaffolds increase cell viability, osteogenic markers, and mineralization 
We anticipate that the most clinically relevant osteoprogenitor cell source at this time are 
bone marrow-derived hMSCs (BM-hMSCs), hence we used these cells to assess cell behavior on 
our iP-hMSC-derived hMatrix. To test cell viability, fresh BM-hMSCs were cultured on the bare 
and bioconditioned scaffolds for 2 days in CCM to allow cells to proliferate before performing 
live/dead staining. Representative images to demonstrate the BM-hMSCs have a spindle-shaped 
morphology on both bare (Fig. 4.5A) and bioconditioned scaffolds (Fig. 4.5B). Summarized results 
from multiple experiments indicate high viability on both bare and bioconditioned scaffolds (Fig. 
4.5C) with a small, but significant, increase in viability observed with the bioconditioned scaffolds. 
Figure 4.5. Live/dead staining of hMSCs present on scaffolds demonstrated an abundance of live cells and sparsely 
distributed dead cells. hMSCs were seeded on top of bare (A) and bioconditioned scaffolds (B) and labeled with 
calcein-AM (green) and propidium iodide (red) to identify live and dead cells. (C) Cell viability 48 hours post-seeding 
was 93.9% (n=3, SD 2.1%) for bare scaffolds, while the bioconditioned scaffolds demonstrated cell viability of 98.2% 
(n=3, SD 0.9%). A two-tailed t-test analysis established that the difference in viability was statistically significant 
(* p<0.05). 
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In order to better understand the regulation of hMatrix deposition, we investigated gene 
expression of collagen VI and XII on BM-hMSCs after 8 days of culture on bare and 
bioconditioned hydrogels. Consistent with previous findings, collagen VI and XII were 
significantly upregulated in response to GW9662 on bare scaffolds in comparison to 
bioconditioned samples.  
In addition to improving cellular retention at an injury site, hMatrix has been shown to 
actively induce the secretion of various osteogenic factors, e.g. BMP2 [97]. Thus, we investigated 
the expression of osteogenic markers osteocalcin (OCN), osteopontin (OPN), and BMP2 after 21 
days of culture on bare and bioconditioned scaffolds, with 10 µM of GW9662 treatment 
administered every 2-3 days.  The fold expression for all three osteogenic markers were 
upregulated on bare scaffolds relative to hMSC monolayer cultures in CCM as a control. The 
bioconditioned samples had significantly higher levels of BMP2 (p=0.02), OPN (p=0.04), and 
OCN (p=0.01) compared to bare scaffolds (Fig. 4.6). 
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Figure 4.6. Bioconditioned scaffolds upregulate osteogenic gene expression. Quantitative RT-PCR analysis showed 
an upregulation of (A) Coll VI and (B) Coll XII in response to GW9662 treatment, but not to bioconditioned scaffolds 
after 8 days of culture. An increase at the transcription level of (C) BMP2, (D) osteocalcin, and (E) osteopontin was 
observed after 21 days of culture on bioconditioned scaffolds. Fold changes were normalized to the expression levels 
of uninduced hMSCs after 8 or 21 days of 2D culture. Statistical analysis was performed using student’s t test on 
calculated ∆∆CT values between bare and bioconditioned samples (* p<0.05). 
A hallmark of late osteogenic differentiation is the mineralization of an underlying matrix. 
Therefore, we investigated the mineral content of bare and freshly decellularized bioconditioned 
scaffolds. In addition, we assessed the mineral content of bare and bioconditioned scaffolds that 
were cultured for an additional 21 days with BM-hMSCs to allow for osteoblast maturation. 
Significantly higher levels of calcium were measured in recently decellularized bioconditioned 
scaffolds and freshly 3D-printed NICE, indicating that the bioconditioned matrix is partially 
mineralized prior to adding BM-hMSCs. Culturing BM-hMSCs on either scaffold substantially 
increased calcium content, but the extent was significantly higher on the bioconditioned scaffolds 
(Fig. 4.7). 
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Figure 4.7. Calcium content on bare and bioconditioned scaffolds. After 21 days of culture, calcium content from (A) 
cultured bare and bioconditioned scaffolds were significantly different, with higher mineralization detected on 
bioconditioned scaffolds. (B) Although significantly different calcium content was detected between freshly printed 
bare scaffolds and recently decellularized bioconditioned scaffolds, levels were low enough to be considered 
inconsequential relative to the cultured scaffolds. Statistical analysis was performed using student’s t test (* p<0.05). 
4.4  Discussion 
A common limitation of synthetic scaffolds used for bone repair is poor bioactive 
properties. We previously demonstrated that NICE scaffolds alone exhibit osteogenic properties 
that are attributed to the activity of nanosilicates [44]. Our new results demonstrate that the 
osteogenic properties of NICE can be enhanced by coating the scaffolds with hMatrix derived from 
iP-hMSCs. While functionalizing synthetic scaffolds/hydrogels with adhesive peptide sequences 
improves cellular attachment and spreading [151], hMatrix represents a physiologically-relevant 
fibrillar matrix with a composition resembling that of regenerating bone [50]. Importantly, hMatrix 
derived from BM-hMSCs improves bone repair in critical sized calvarial and femoral defects [50, 
97]. BM-hMSCs pose several challenges to scaling up hMatrix production for clinical use, 
including donor variance and senescence that would necessitate frequent cell batch validation. 
Thus, iP-hMSCs were employed since undifferentiated iPSCs can be passaged indefinitely prior 
to differentiation.  
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Titanium sheets and meshes can be fabricated using 3D printing techniques such as direct 
metal laser sintering [152]. Although the use of titanium has proved useful in the clinic, this 
material cannot be replaced by ingrowing bone or function as a carrier for bioactive molecules 
[153, 154]. Stiff and bioactive ceramic-based inks are available for 3D printing of patient-specific 
bone grafts for CMF repair, but result in brittle properties [155]. Polymers, such as polylactic acid 
(PLA), poly(caprolactone) (PCL), polyether ether ketone (PEEK), have been printed to fabricate 
CMF constructs, but require organic solvents or high temperatures [155]. We have previously 
demonstrated that NICE is capable of high-fidelity printing under cytocompatible conditions 
[148], thus indicating the potential to fabricate bioconditioned NICE scaffolds with encapsulated 
hMSCs. In the present work, we performed an initial study demonstrating that NICE can be used 
to fabricating osteogenic constructs to fill CMF defect geometries extracted from µCT images. 
Further, coating the NICE scaffolds with hMatrix results in higher osteogenic activity in BM-
hMSCs than if the cells were cultured on bare NICE scaffolds alone. Future work will explore 
more sophisticated approaches for this bone graft strategy, such as co-extrusion of hMatrix and 
hMSCs in NICE. 
BM-hMSCs treated with GW9662 express high levels of several collagens enriched in 
developing bone, including collagens V [156], VI [157], XI [156], XII and XIV [15]. Experiments 
using blocking antibodies indicate that collagens VI and XII each contribute to the osteogenic 
properties of hMatrix [97]. The presence of collagens VI and XII in the matrix deposited by the 
GW9662-treated iP-hMSCs. Further, this matrix enhanced the expression of OPN, OCN and 
BMP2 in BM-hMSCs. These data indicate that the matrix deposited by iP-hMSCs onto NICE 
scaffolds has the same properties as that deposited by BM-hMSCs onto Gelfoam in our previous 
studies in both 2D [50] and 3D culture [97]. While bare NICE scaffolds supported the robust 
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expression of collagens VI and XII in BM-hMSCs, there were much lower levels of expression 
from the same cells cultured on NICE already coated with matrix containing collagens VI and XII. 
Transcriptome analyses indicate that BM-hMSCs treated with GW9662 express genes involved in 
integrin/focal adhesion signaling [97], suggesting that adhesion to collagens VI and XII results in 
negative feedback in collagens VI and XII expression on bioconditioned NICE. 
We hypothesized that by providing a microenvironment that more closely mimics bone 
undergoing repair would enhance the osteogenic properties of NICE-based scaffolds. Examination 
of three osteogenic markers―BMP2, osteopontin, and osteocalcin―did in fact reveal an overall 
increase in their expression in bioconditioned NICE relative to bare NICE. It is important to note 
the expression levels seen in bare NICE is a product of the inherent osteogenic properties of NICE 
coupled with GW9662 treatment. Given that both collagens VI and XII were highly expressed in 
cells cultured on bare NICE after 8 days of culture indicates that bare NICE was undergoing the 
bioconditioning process. Given the role osteopontin plays in mineralization and improved 
calcification seen in BM-hMSCs treated with nSil [158], we investigated calcium content as an 
additional late stage marker. Freshly printed NICE showed low levels of calcification, indicating 
that the divalent cations present in nSil did not interfere with the o-cresolphthalein based assay. 
We have previously observed levels of calcium phosphate in purified hMatrix derived from BM-
hMSCs cultured in polystyrene [50]. Similar results were encountered when recently 
decellularized bioconditioned NICE were evaluated, showing significantly higher levels of 
calcification compared to freshly printed bare NICE. Predictably, evaluation of calcium content 
after 21 days of culture further increased calcium levels in both bare and bioconditioned NICE. 
Although the initial quantity of calcium bioconditioned scaffolds started with was higher than bare 
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scaffolds, further inspection revealed the bioconditioning process contributed a small percentage 
of the final calcium content (~3%). 
Because of their bioinstructive properties, ECM proteins and their binding domains have 
been used to enhance the bone repair capabilities of scaffolds [97, 127, 130, 159, 160]. Methods 
to functionalize these motifs onto scaffolds include: adsorption from protein stock solutions [127], 
covalent tethering [161], and direct cell-culture deposition [130, 159, 160]. Decellularized 
extracellular matrices derived from tissue culture plastic can be purified for downstream use 
(adsorption or covalent tethering). In addition, the composition of the decellularized matrix can be 
altered by varying the culture duration, which can influence the behavior of newly seeded 
progenitor cells. For example, murine MSCs cultured on more mature, i.e. more mineralized, 
decellularized matrices were observed to have higher alkaline phosphatase activity, but also 
reduced cellular proliferation [159]. It should be mentioned that the decellularization and 
homogenization process can have deleterious effects on protein structures and interactions that 
could be modulating cell function. Thus, care must be taken to ensure the complex extracellular 
matrix remains intact. Alternatively, direct deposition of ECM onto established scaffolds allows 
for the fabrication of scaffolds with desired geometries and composition, e.g. titanium meshes 
[162]. In the present work, we chose to 3D print our scaffold as it allows a high degree of control 
of the construct geometry. Unlike 3D printed scaffolds based on synthetic materials, NICE is 
enzymatically-degradable and can be remodeled in vivo. A 100% infill density was used for the 
cell culture work in order to ensure cells were confined to the surface, thus circumventing issues 
with nutrient and oxygen transport. Future work will focus on coupling scaffolds with reduced 
infill density with a perfusion bioreactor system. This would allow for improved cell infiltration 
and ECM deposition. Furthermore due to the angiogenic properties of hMatrix, the resulting 
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mesh/channels from a reduced infill density will likely facilitate vascularization that could be 
stimulated by the angiogenic factors produced by hMSCs in response to attachment to hMatrix 
[97].  
4.5  Conclusion 
We have successfully demonstrated the feasibility of generating 3D printed NICE scaffolds 
for patient-specific craniomaxillofacial defects with high print fidelity. Printed scaffolds are 
resilient and tough, permitting manual manipulation and are compressible, allowing a press-fit into 
the defect. The scaffolds that were modified with a stem cell-derived extracellular matrix exhibited 
an increase in osteogenic gene expression and mineralization. The decellularized 3D printed 
scaffolds described here may be utilized as an alternative to autologous grafts for orthopedic 
procedures. Due to the promising biological and physical properties of NICE grafts created with 
3D printing and bioconditioning, this system will be evaluated for bone regeneration in vivo for 
spinal fusion in the near future. 
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5. CONCLUSIONS
5.1  Summary 
The body of work presented here details the utility of a cell-derived extracellular-matrix 
coating for enhancing cellular response and tissue repair. This work builds upon work by Dr. 
Gregory’s group which developed a method for creating osteogenically enhanced human 
mesenchymal stem cells (OEhMSCs). These OEhMSCs secrete an extracellular matrix, termed 
hMatrix, which enhances stem cell retention and bone regeneration. Critical components in the 
development of this work include novel methods for the fabrication, culture, and delivery of the 
scaffold, as well as recent development in bioinks and biomanufacturing of custom scaffolds to 
enable patient-specific implantable scaffolds. These results have been validated with significant in 
vitro work and preclinical calvarial and femoral defects in animal models. 
In order to create a more versatile graft material, a custom, 3D-printed microfluidic device 
was designed that creates uniform microspheres ranging 90-250 µm. This enabled the use of a 3D 
culture system with enhanced surface area on which to seed cells and deposit hMatrix. This ECM 
has been found to contain increased levels of collagen VI and XII; similar in composition to 
regenerating bone. The deposition of this hMatrix on the surface of these microspheres, a process 
we term bioconditioning, also results in enhanced osteogenic and angiogenic activity. Delivery of 
the bioconditioned scaffold in conjunction with OEhMSCs resulted in significant healing in both 
calvarial and femoral murine models, comparable to the clinical gold standard collagen sponge 
soaked in BMP-2.  
To show the adaptability of this bioconditioning process, it was also used in conjunction 
with bioprinting to create a custom-fit graft. This specific work built upon the development of a 
NICE bioink created by Chimene, et al. which is tough and resilient, but degradable and conducive 
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to cell growth. The NICE bioink consists of a nanosilicate (N), ionically crosslinked κ-carageenan 
(I), covalently crosslinked gelatin methacrylate (C), and its impressive mechanical and rheological 
properties are attributed to the entanglement of these components (E). This ink was used to create 
complementary, 3D bioprinted scaffolds that were then bioconditioned and evaluated in vitro. 
Similar to the performance of the injectable microsphere system, bioconditioned scaffolds seeded 
with OEhMSCs showed increased levels of collagen VI and XII and resulted in enhanced 
osteogenic activity and calcium deposition.  
This work demonstrates a novel bone graft with safety and efficacy surpassing BMP2 
Specifically, we have developed a manufacturing method that is potentially scalable and 
demonstrates a versatile, injectable scaffold platform, as well as potential use as a customizable, 
patient-specific, tissue engineered implant. Furthermore, these bioconditioned scaffolds address 
current limitations of autografts and allografts by providing a bioactive, cell-derived material 
without the need for harvest from the patient, or risk of disease transmission from a donor. 
Furthermore, the technology developed from this work can be used to design future bioconditioned 
scaffolds for tissue engineering other target tissues.  
5.2 Significance of Work 
The aim of this work is to develop a tissue engineered graft that promotes bone regeneration 
by mimicking the niche of regenerating bone. In doing so, we demonstrate a full-featured bone 
graft material that is biodegradable, osteoinductive, and compatible with current surgical practices. 
Injectable, bioconditioned microspheres are able to enhance bone grafting procedures by space 
filling the defect to promote bone regeneration, providing osteogenic and angiogenic cues to 
promote bone growth and vascularization, and delivering OEhMSCs to promote bone 
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regeneration. This technology provides a methodology for creating highly regenerative graft 
materials that can replace the need for autologous bone grafts.  
Chapter 2 investigates different methods of fabricating hMatrix derived microspheres to 
determine which method is optimal for future scale-up potential. GelMA microspheres were 
fabricated and bioconditioned for use in in vitro studies. Prior to this, hMatrix or hMatrix-coated 
gelatin scaffolds were used, but not in an injectable form. Designing an injectable scaffold that 
improves the retention of administered stem cells is currently a major issue in tissue engineering 
as the injected cells usually are not retained at the defect past the regenerative phase of bone repair 
[50]. In contrast to the first generation of PEGDA microspheres with functionalized hMatrix, the 
bioconditioned GelMA microspheres are degradable and will allow for tissue ingrowth and 
remodeling. Additionally, microspheres have a high surface area to volume ratio to amplify the 
production of hMatrix. The development of this 3D fabrication and culture platform represents a 
framework for biomanufacturing of various graft materials and biologicals for other tissues.  
The recent advances in rapid prototyping and imaging modalities have made it possible to 
fabricate patient specific implants to precisely fit anatomical defects. To show this process could 
be used in a potential clinical setting, we demonstrate its application to 3D bioprinted parts created 
from a CT scan of an artificially created skull defect. Building upon the development of tough and 
resilient NICE bioink created by Chimene, et al., we created bioconditioned implantable scaffolds 
with unprecedented osteogenic potential. These scaffolds performed comparably to the 
bioconditioned microspheres, but did not rely on the void left in the target tissue to dictate its 
shape. Rather, these custom bioprinted scaffolds showcase the versatility of the bioconditioning 
process, and its ability to create structures that are custom designed for the patient. Custom grafts 
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could improve tissue integration compared to off-the-shelf implants, reducing costs and 
complications. 
In summary, these studies have resulted in a method to coat microspheres and 3D printed 
scaffolds with a cell-derived matrix that mimics regenerating bone that can be used to advance 
bone tissue engineering. Beyond tissue engineering, these studies have also investigated methods 
that are best for future scale-up potential. 
5.3 Future Work 
This work details the development of tissue engineered bone scaffolds with enhanced 
regeneration by utilizing osteogenically-enhanced hMSCs and hMatrix. We present improvements 
in scaffold delivery, osteogenic potential in vitro, and bone regeneration in vivo. However, 
additional studies are needed to further optimize bioconditioned scaffolds and assess future scale 
up potential.  
A primary focus of this work was to develop a method for 3D culture, biocondition GelMA 
microspheres, and evaluate hMSC-hMatrix interactions. It was demonstrated that microspheres 
could be cultured in a 3D suspension culture environment to facilitate the bioconditioning process, 
and that this resulted in enhanced osteogenic growth factor secretion and osteogenic gene 
expression. While the enhanced osteoegenesis and bone formation can be attributed to the 
deposited matrix, it remains unclear whether this is primarily due to hMatrix composition or 
resulting increase in the surface stiffness. The preliminary AFM studies in Chapter 2 demonstrated 
proof of principle protocols that allowed for AFM measurements on GelMA and bioconditioned 
GelMA hydrogels. However, the substantial variability between samples led to a statistically 
insignificant result, motivating a study with a larger sample size.  
79 
Another common issue with current bone grafting procedures is the use of donor-derived 
hMSCs. The effectiveness of these therapies are constrained by variability in cell quality based on 
the health status of the donor and processing steps used to expand cells. However, since the end 
product of this process is acellular, autologous cells are not necessary. Instead, iPSCs can be used 
to produce iPSC-derived hMSCs, which can theoretically be expanded indefinitely to produce 
large amounts of bioconditioned microspheres with reliable properties. Further, iPSC-derived 
hMSCs produce hMatrix in higher quantities than that produced by hMSCs. While the initial 
microsphere studies used donor-derived hMSCs, bioconditioning of the 3D printed grafts was 
performed with iPSC-derived hMSCs, and will be utilized in future studies with the GelMA 
microsphere system. The iPSC-based microsphere system should therefore be tested in vitro for 
angiogenic and osteogenic capacity as well as in animal models to compare the bone healing 
capacity.  
In these initial experiments, the rotating wall vessel (RWV) bioreactors are well-suited for 
laboratory scale experiments. However, these RWV bioreactors are not scalable to a degree 
sufficient for biomanufacturing. Therefore, these experiments should be repeated in vertical wheel 
bioreactors or stirred tank currently used in industry and can be scaled up to manufacture 
bioconditioned microspheres. iPSC-derived hMSCs should be expanded on the GelMA 
microspheres to establish optimal cell culture conditions and the cells should be evaluated using 
in vitro functional assays for cell viability, differentiation into mesenchymal tissue types, and 
immune modulation.  
While the final bioconditioned scaffold is acellular, the decellularization process and 
residual proteins are an important concern. The in vivo studies performed in this work were 
performed on nude mice that do not have a thymus and therefore have an inhibited immune system. 
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Future studies should include immunocompetent animals to see if these constructs have the ability 
to evade immune rejection.  
The bioconditioned NICE scaffolds should also undergo further scaffold characterization. 
More studies should be conducted to investigate if bioconditioning alters the scaffold architecture 
and properties such as water contact angle, SEM, swelling ratio, porosity, and compression tests. 
Additional studies are also needed to further assess bone formation in vivo. After much further 
development, this process could also be augmented to create more complex, multi-material 
scaffolds with integrated vascular networks to improve tissue integration and overall healing. 
While additional research is needed before these bioconditioned scaffolds can be utilized 
as a clinical option for bone grafting procedures, a novel technology has been developed that can 
be readily tuned for future studies. Protocols were established to utilize the bioconditioning process 
for microspheres in suspension culture and for custom 3D printed scaffolds. Overall these 
bioconditioned scaffolds are a promising bone graft substitute, providing a novel material with 
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